

=> fil cap
 FILE 'CAPLUS' ENTERED AT 11:28:38 ON 14 MAR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 14 Mar 2008 VOL 148 ISS 12
 FILE LAST UPDATED: 13 Mar 2008 (20080313/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que 15

L1 STR



VAR G1=H/15/18/22/AK/CY
 VAR G2=NH2/24/27
 VAR G4=H/OH/29/NH2/24/27/CN/AK/CY
 VAR G5=35/32
 VAR G6=AK/CY
 NODE ATTRIBUTES:
 CONNECT IS E1 RC AT 16
 CONNECT IS E1 RC AT 20
 CONNECT IS E1 RC AT 25
 CONNECT IS E1 RC AT 26
 CONNECT IS E1 RC AT 28
 CONNECT IS E1 RC AT 30
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 11
 GGCAT IS UNS AT 35
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L3 927 SEA FILE=REGISTRY SSS FUL L1
L4 9 SEA FILE=CAPLUS ABB=ON PLU=ON L3
L5 6 SEA FILE=CAPLUS ABB=ON PLU=ON L4 AND (PY<2004 OR AY<2004 OR
PRY<2004)

=> d 15 ibib abs hitstr tot

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:472131 CAPLUS Full-text
DOCUMENT NUMBER: 143:26620
TITLE: Preparation of pyridazin-3(2H)-ones and their use as
PDE4 inhibitors
INVENTOR(S): Dal Piaz, Vittorio; Aguilar Izquierdo, Nuria; Buil
Albero, Maria Antonia; Garrido Rubio, Yolanda;
Giovannoni Maria, Paola; Gracia Ferrer, Jordi; Lumeras
Amador, Wenceslao; Vergelli, Claudia
PATENT ASSIGNEE(S): Almirall Prodesfarma, S. A., Spain
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049581	A1	20050602	WO 2004-EP12604	20041108 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2232306	A1	20050516	ES 2003-2613	20031110 <--
ES 2232306	B1	20060801		
AU 2004291282	A1	20050602	AU 2004-291282	20041108 <--
CA 2545193	A1	20050602	CA 2004-2545193	20041108 <--
EP 1682519	A1	20060726	EP 2004-797700	20041108 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1878759	A	20061213	CN 2004-80033113	20041108 <--
BR 2004016212	A	20070102	BR 2004-16212	20041108 <--
JP 2007510689	T	20070426	JP 2006-538762	20041108 <--
IN 2006DN01703	A	20070831	IN 2006-DN1703	20060329 <--
MX 2006PA05101	A	20060714	MX 2006-PA5101	20060504 <--
KR 2007001907	A	20070104	KR 2006-711454	20060609 <--
NO 2006002726	A	20060612	NO 2006-2726	20060612 <--
US 2007197536	A1	20070823	US 2007-578594	20070215 <--

PRIORITY APPLN. INFO.:

ES 2003-2613

A 20031110 <--


WO 2004-EP12604

W 20041108

OTHER SOURCE(S):

MARPAT 143:26620

GI



AB Title compds. I [R1-2 = H, acyl, alkoxy, carbonyl, etc.; R3 = mono/polycyclic (hetero)aryl, etc.; R4 = H, OH, alkoxy, amino, etc.; R5 = carboxy, mono/polycyclic (hetero)aryl, etc.] are prepared For instance, 1-Ethyl-3-(4-fluorophenyl)-6-oxo-5-((pyridin-3-yl)amino)-1,6-dihydropyridazine-4-carbonitrile (II) is prepared from 5-Amino-1-ethyl-3-(4-fluorophenyl)-6-oxo-1,6-dihydropyridazine-4-carbonitrile (preparation given) and 3-bromopyridine. II has IC50 = 5.4 for PDE4. I are useful for the treatment of asthma, COPD, etc.

IT 852617-87-9P, 4-[(3-Chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one 852617-88-0P, 4-[(3-Chlorophenyl)amino]-2-ethyl-5-(1-methoxyethyl)-6-phenylpyridazin-3(2H)-one 852617-89-1P, 4-[(3-Chlorophenyl)amino]-2-ethyl-6-phenyl-5-vinylpyridazin-3(2H)-one 852617-90-4P, 4-Anilino-2,5-diethyl-6-phenylpyridazin-3(2H)-one 852617-91-5P 852617-92-6P, 5-[(3-Chlorophenyl)amino]-1-ethyl-6-oxo-3-phenyl-1,6-dihydropyridazine-4-carbonitrile 852617-93-7P, 1-Ethyl-5-[[4-(hydroxymethyl)phenyl]amino]-6-oxo-3-phenyl-1,6-dihydropyridazine-4-carbonitrile 852617-94-8P, 1-Ethyl-6-oxo-3-phenyl-5-[(3,4,5-trifluorophenyl)amino]-1,6-dihydropyridazine-4-carbonitrile 852617-95-9P, 5-[(4-Cyanophenyl)amino]-1-ethyl-6-oxo-3-phenyl-1,6-dihydropyridazine-4-carbonitrile 852617-96-0P, 1-Ethyl-3-(4-fluorophenyl)-5-[[4-(hydroxymethyl)phenyl]amino]-6-oxo-1,6-dihydropyridazine-4-carbonitrile 852617-97-1P, 5-[(4-Cyanophenyl)amino]-1-ethyl-3-(4-fluorophenyl)-6-oxo-1,6-dihydropyridazine-4-carbonitrile 852617-98-2P, 1-Ethyl-3-(4-fluorophenyl)-6-oxo-5-[(3,4,5-trifluorophenyl)amino]-1,6-dihydropyridazine-4-carbonitrile 852617-99-3P, 1-Ethyl-3-(4-fluorophenyl)-6-oxo-5-((pyridin-3-yl)amino)-1,6-dihydropyridazine-4-carbonitrile 852618-00-9P, 1-Ethyl-3-(3-fluorophenyl)-5-[[4-(hydroxymethyl)phenyl]amino]-6-oxo-1,6-dihydropyridazine-4-carbonitrile 852618-01-0P, 5-[(4-Cyanophenyl)amino]-1-ethyl-3-(3-fluorophenyl)-6-oxo-1,6-dihydropyridazine-4-carbonitrile 852618-02-1P, 1-Ethyl-3-(3-fluorophenyl)-6-oxo-5-[(3,4,5-trifluorophenyl)amino]-1,6-dihydropyridazine-4-carbonitrile 852618-03-2P, 4-[(3-Chlorophenyl)amino]-2-ethyl-5-(2-methyl-1,3-thiazol-4-yl)-6-phenylpyridazin-3(2H)-one 852618-04-3P 852618-05-4P 852618-06-5P, 4-[[2-Ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl]amino]benzonitrile 852618-07-6P, 2-Ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-6-phenyl-4-[(3,4,5-trifluorophenyl)amino]pyridazin-3(2H)-one 852618-08-7P, 4-[(3-Chlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one


852618-09-8P, 2-Ethyl-4-[(3-fluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 852618-10-1P, 2-Ethyl-4-(1-naphthylamino)-6-phenylpyridazin-3(2H)-one 852618-11-2P, 2-Ethyl-6-phenyl-4-((pyridin-3-yl)amino)pyridazin-3(2H)-one 852618-12-3P, 2-Ethyl-6-phenyl-4-((quinolin-5-yl)amino)pyridazin-3(2H)-one 852618-13-4P, 4-[Bis(3,4,5-trifluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 852618-14-5P, 4-[Bis(3,4-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 852618-15-6P, 4-[(3,4-Difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 852618-16-7P, 4-[(3-Chloro-4-fluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 852618-17-8P, 4-[(2-Ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzonitrile 852618-18-9P, 2-Ethyl-4-[(1-oxopyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one 852618-19-0P, 2-Ethyl-6-pyridin-3-yl-4-((pyridin-3-yl)amino)pyridazin-3(2H)-one 852618-20-3P, 2-Ethyl-4-[(1-oxoquinolin-5-yl)amino]-6-phenylpyridazin-3(2H)-one 852618-21-4P, 2-Ethyl-6-(pyridin-4-yl)-4-((pyridin-3-yl)amino)pyridazin-3(2H)-one 852618-22-5P, 2-Ethyl-4-((isoquinolin-4-yl)amino)-6-phenylpyridazin-3(2H)-one 852618-23-6P, 2-Ethyl-6-phenyl-4-[(3,4,5-trifluorophenyl)amino]pyridazin-3(2H)-one 852618-24-7P, 2-Ethyl-4-[(4-fluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 852618-25-8P, 2-Ethyl-6-pyridin-3-yl-4-((quinolin-5-yl)amino)pyridazin-3(2H)-one 852618-26-9P, 2-Methyl-6-pyridin-3-yl-4-((quinolin-5-yl)amino)pyridazin-3(2H)-one 852618-27-0P, 2-Ethyl-6-pyridin-4-yl-4-((quinolin-5-yl)amino)pyridazin-3(2H)-one 852618-28-1P, 2-Ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 852618-29-2P, 4-[(2-Methyl-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazin-4-yl)amino]benzonitrile 852618-30-5P, 4-[(2-Ethyl-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazin-4-yl)amino]benzonitrile 852618-31-6P, Methyl 4-[(2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoate 852618-32-7P, 4-[[2-Ethyl-6-(1-oxopyridin-3-yl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 852618-33-8P, 2-Ethyl-4-((isoquinolin-4-yl)amino)-6-(pyridin-3-yl)pyridazin-3(2H)-one 852618-34-9P, 2-Ethyl-4-[(4-methylpyridin-3-yl)amino]-6-(pyridin-3-yl)pyridazin-3(2H)-one 852618-35-0P, 2-Ethyl-4-((isoquinolin-4-yl)amino)-6-(pyridin-4-yl)pyridazin-3(2H)-one 852618-36-1P, 4-[(2-Ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid 852618-37-2P, 2-Ethyl-4-[(4-methylpyridin-3-yl)amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 852618-38-3P, 4-[(2-Ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)(methyl)amino]benzonitrile 852618-39-4P, N-(4-Cyanophenyl)-N-(2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)acetamide 852618-40-7P, 6-(3-Chlorophenyl)-2-ethyl-4-((pyridin-3-yl)amino)pyridazin-3(2H)-one 852618-41-8P, 2-Ethyl-4-[methyl(quinolin-5-yl)amino]-6-phenylpyridazin-3(2H)-one 852618-42-9P, 6-(3-Chlorophenyl)-2-ethyl-4-((isoquinolin-4-yl)amino)pyridazin-3(2H)-one 852618-43-0P, N-(2-Ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)-N-quinolin-5-ylacetamide 852618-44-1P, 2-Ethyl-4-[(4-(hydroxymethyl)phenyl)amino]-6-(pyridin-3-yl)pyridazin-3(2H)-one 852618-45-2P, 2-Ethyl-4-((isoquinolin-4-yl)amino)-6-(4-methoxyphenyl)pyridazin-3(2H)-one 852618-46-3P, 2-Ethyl-6-(4-methoxyphenyl)-4-((quinolin-5-yl)amino)pyridazin-3(2H)-one 852618-47-4P, 4-Anilino-2-ethyl-6-phenylpyridazin-3(2H)-one 852618-48-5P, 2-Ethyl-6-(4-methylphenyl)-4-((quinolin-5-yl)amino)pyridazin-3(2H)-one 852618-49-6P, 2-Ethyl-6-(4-methylphenyl)-4-[(1-oxoquinolin-5-yl)amino]pyridazin-3(2H)-one 852618-50-9P, 2-Ethyl-6-phenyl-4-((thieno[2,3-c]pyridin-3-yl)amino)pyridazin-3(2H)-one 852618-51-0P, 1-Ethyl-6-oxo-3-phenyl-5-((pyridin-3-yl)amino)-1,6-dihydropyridazine-4-

carbonitrile 852618-52-1P, 1-Ethyl-3-(3-methylphenyl)-6-oxo-5-
 ((pyridin-3-yl)amino)-1,6-dihydropyridazine-4-carbonitrile
 852618-53-2P, 2-Ethyl-5-(1-hydroxyethyl)-6-phenyl-4-((quinolin-5-
 yl)amino)pyridazin-3(2H)-one 852618-54-3P, 2-Ethyl-6-(4-
 methylphenyl)-4-((pyridin-3-yl)amino)pyridazin-3(2H)-one
 852618-55-4P, 2-Ethyl-4-((isoquinolin-4-yl)amino)-6-(4-
 methylphenyl)pyridazin-3(2H)-one 852618-56-5P,
 2-Ethyl-6-(4-methylphenyl)-4-[(4-methylpyridin-3-yl)amino]pyridazin-3(2H)-
 one 852618-57-6P, 2-Ethyl-6-(3-methylphenyl)-4-((pyridin-3-
 yl)amino)pyridazin-3(2H)-one 852618-58-7P, 2-Ethyl-4-
 ((isoquinolin-4-yl)amino)-6-(3-methylphenyl)pyridazin-3(2H)-one
 852618-59-8P, 2-Ethyl-6-(3-methylphenyl)-4-[(4-methylpyridin-3-
 yl)amino]pyridazin-3(2H)-one 852618-60-1P, 4-[[2-Ethyl-6-(3-
 methylphenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzoic acid
 852618-61-2P, 2-Ethyl-6-(5-methylpyridin-3-yl)-4-((pyridin-3-
 yl)amino)pyridazin-3(2H)-one 852618-62-3P, 2-Ethyl-4-
 ((isoquinolin-4-yl)amino)-6-(5-methylpyridin-3-yl)pyridazin-3(2H)-one
 852618-63-4P, 2-Ethyl-6-(5-methylpyridin-3-yl)-4-[(4-methylpyridin-
 3-yl)amino]pyridazin-3(2H)-one 852618-64-5P 852618-65-6P
 , [1-Ethyl-6-oxo-3-phenyl-5-((pyridin-3-yl)amino)-1,6-dihydropyridazin-4-
 yl]methyl acetate 852618-66-7P 852618-67-8P,
 2-Ethyl-5-[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]-6-phenyl-4-((pyridin-3-
 yl)amino)pyridazin-3(2H)-one 852618-68-9P, 2-Ethyl-4-
 ((isoquinolin-4-yl)amino)-6-(6-methylpyridin-3-yl)pyridazin-3(2H)-one
 852618-69-0P, 2-Ethyl-6-(6-methylpyridin-3-yl)-4-((pyridin-3-
 yl)amino)pyridazin-3(2H)-one 852618-70-3P, 2-Ethyl-5-[2-(4-
 methoxyphenyl)-1,3-thiazol-4-yl]-4-[(4-methylpyridin-3-yl)amino]-6-
 phenylpyridazin-3(2H)-one 852618-71-4P 852618-72-5P,
 Ethyl 4-[1-ethyl-6-oxo-3-phenyl-5-((pyridin-3-yl)amino)-1,6-
 dihydropyridazin-4-yl]-1,3-thiazole-2-carboxylate 852618-73-6P,
 2-Ethyl-4-((isoquinolin-4-yl)amino)-5-[2-(4-methoxyphenyl)-1,3-thiazol-4-
 yl]-6-phenylpyridazin-3(2H)-one 852618-74-7P,
 2-Ethyl-4-[(4-methylpyridin-3-yl)amino]-6-phenyl-5-(2-pyridin-4-yl-1,3-
 thiazol-4-yl)pyridazin-3(2H)-one 852618-75-8P,
 5-[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]-2-ethyl-4-[(4-methylpyridin-3-
 yl)amino]-6-phenylpyridazin-3(2H)-one 852618-76-9P
 852618-77-0P, 5-[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]-2-ethyl-4-
 ((isoquinolin-4-yl)amino)-6-phenylpyridazin-3(2H)-one 852618-78-1P
 , 2-Ethyl-4-[(4-methylpyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one
 852618-79-2P, 2-Ethyl-4-[(4-methyl-1-oxopyridin-3-yl)amino]-6-
 phenylpyridazin-3(2H)-one 852618-80-5P, Ethyl
 4-[(2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyridazin-3(2H)-ones and their use as PDE4 inhibitors)


RN 852617-87-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-
 phenyl- (CA INDEX NAME)




RN 852617-88-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-methoxyethyl)-6-phenyl- (CA INDEX NAME)




RN 852617-89-1 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-5-ethenyl-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 852617-90-4 CAPLUS

CN 3(2H)-Pyridazinone, 2,5-diethyl-6-phenyl-4-(phenylamino)- (CA INDEX NAME)




RN 852617-91-5 CAPLUS

CN 4-Pyridazinecarboxaldehyde, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl-, 4-(O-methyloxime) (CA INDEX NAME)




RN 852617-92-6 CAPLUS

CN 4-Pyridazinecarbonitrile, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl- (CA INDEX NAME)




RN 852617-93-7 CAPLUS

CN 4-Pyridazinecarbonitrile, 1-ethyl-1,6-dihydro-5-[[4-(hydroxymethyl)phenyl]amino]-6-oxo-3-phenyl- (CA INDEX NAME)




RN 852617-94-8 CAPLUS

CN 4-Pyridazinecarbonitrile, 1-ethyl-1,6-dihydro-6-oxo-3-phenyl-5-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 852617-95-9 CAPLUS

CN 4-Pyridazinecarbonitrile, 5-[(4-cyanophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl- (CA INDEX NAME)




RN 852617-96-0 CAPLUS

CN 4-Pyridazin-3-ynitrile, 1-ethyl-3-(4-fluorophenyl)-1,6-dihydro-5-[[4-(hydroxymethyl)phenyl]amino]-6-oxo- (CA INDEX NAME)




RN 852617-97-1 CAPLUS

CN 4-Pyridazin-3-ynitrile, 5-[(4-cyanophenyl)amino]-1-ethyl-3-(4-fluorophenyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 852617-98-2 CAPLUS

CN 4-Pyridazin-3-ynitrile, 1-ethyl-3-(4-fluorophenyl)-1,6-dihydro-6-oxo-5-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 852617-99-3 CAPLUS

CN 4-Pyridazinecarbonitrile, 1-ethyl-3-(4-fluorophenyl)-1,6-dihydro-6-oxo-5-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-00-9 CAPLUS

CN 4-Pyridazinecarbonitrile, 1-ethyl-3-(3-fluorophenyl)-1,6-dihydro-5-[[4-(hydroxymethyl)phenyl]amino]-6-oxo- (CA INDEX NAME)




RN 852618-01-0 CAPLUS

CN 4-Pyridazinecarbonitrile, 5-[(4-cyanophenyl)amino]-1-ethyl-3-(3-fluorophenyl)-1,6-dihydro-6-oxo- (CA INDEX NAME)




RN 852618-02-1 CAPLUS

CN 4-Pyridazinecarbonitrile, 1-ethyl-3-(3-fluorophenyl)-1,6-dihydro-6-oxo-5-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 852618-03-2 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-5-(2-methyl-4-thiazolyl)-6-phenyl- (CA INDEX NAME)




RN 852618-04-3 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-6-phenyl-5-(2-phenyl-4-thiazolyl)- (CA INDEX NAME)




RN 852618-05-4 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-methyl-1H-pyrazol-5-yl)-6-phenyl- (CA INDEX NAME)




RN 852618-06-5 CAPLUS

CN Benzonitrile, 4-[[2-ethyl-2,3-dihydro-5-(5-methyl-1,3,4-oxadiazol-2-yl)-3-oxo-6-phenyl-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 852618-07-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-6-phenyl-4-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 852618-08-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 852618-09-8 CAPLUS


CN 3(2H)-Pyridazinone, 2-ethyl-4-[(3-fluorophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 852618-10-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-ethyl-4-(1-naphthalenylamino)-6-phenyl- (CA INDEX NAME)




RN 852618-11-2 CAPLUS
 CN 3(2H)-Pyridazinone, 2-ethyl-6-phenyl-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-12-3 CAPLUS
 CN 3(2H)-Pyridazinone, 2-ethyl-6-phenyl-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 852618-13-4 CAPLUS

CN 3(2H)-Pyridazinone, 4-[bis(3,4,5-trifluorophenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)

RN 852618-14-5 CAPLUS


CN 3(2H)-Pyridazinone, 4-[bis(3,4-difluorophenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)

RN 852618-15-6 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3,4-difluorophenyl)amino]-2-ethyl-6-phenyl- (CA
INDEX NAME)


RN 852618-16-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)




RN 852618-17-8 CAPLUS

CN Benzonitrile, 4-[(2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-
(CA INDEX NAME)




RN 852618-18-9 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(1-oxido-3-pyridinyl)amino]-6-phenyl- (CA
INDEX NAME)




RN 852618-19-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(3-pyridinyl)-4-(3-pyridinylamino)- (CA
INDEX NAME)




RN 852618-20-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(1-oxido-5-quinolinyl)amino]-6-phenyl- (CA
INDEX NAME)




RN 852618-21-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(4-pyridinyl)-4-(3-pyridinylamino)- (CA
INDEX NAME)




RN 852618-22-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-6-phenyl- (CA INDEX
NAME)




RN 852618-23-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-phenyl-4-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 852618-24-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(4-fluorophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 852618-25-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(3-pyridinyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 852618-26-9 CAPLUS

CN 3(2H)-Pyridazinone, 2-methyl-6-(3-pyridinyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 852618-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(4-pyridinyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 852618-28-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 852618-29-2 CAPLUS

CN Benzonitrile, 4-[[[2,3-dihydro-2-methyl-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 852618-30-5 CAPLUS

CN Benzonitrile, 4-[[[2-ethyl-2,3-dihydro-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 852618-31-6 CAPLUS

CN Benzoic acid, 4-[(2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, methyl ester (CA INDEX NAME)




RN 852618-32-7 CAPLUS

CN Benzonitrile, 4-[[2-ethyl-2,3-dihydro-6-(1-oxido-3-pyridinyl)-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 852618-33-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 852618-34-9 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(4-methyl-3-pyridinyl)amino]-6-(3-pyridinyl)- (CA INDEX NAME)




RN 852618-35-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 852618-36-1 CAPLUS

CN Benzoic acid, 4-[(2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 852618-37-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(4-methyl-3-pyridinyl)amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 852618-38-3 CAPLUS

CN Benzonitrile, 4-[(2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)methylamino]- (CA INDEX NAME)




RN 852618-39-4 CAPLUS

CN Acetamide, N-(4-cyanophenyl)-N-(2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)- (CA INDEX NAME)



RN 852618-40-7 CAPLUS


CN 3(2H)-Pyridazinone, 6-(3-chlorophenyl)-2-ethyl-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-41-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(methyl-5-quinolinylamino)-6-phenyl- (CA INDEX NAME)


INDEX NAME)



RN 852618-42-9 CAPLUS


CN 3(2H)-Pyridazinone, 6-(3-chlorophenyl)-2-ethyl-4-(4-isoquinolinylamino)-
(CA INDEX NAME)

RN 852618-43-0 CAPLUS

CN Acetamide, N-(2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)-N-5-
quinolinyl- (CA INDEX NAME)


RN 852618-44-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(3-
pyridinyl)- (CA INDEX NAME)




RN 852618-45-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-6-(4-methoxyphenyl)-
(CA INDEX NAME)




RN 852618-46-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(4-methoxyphenyl)-4-(5-quinolinylamino)-
(CA INDEX NAME)




RN 852618-47-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-phenyl-4-(phenylamino)- (CA INDEX NAME)




RN 852618-48-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(4-methylphenyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 852618-49-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(4-methylphenyl)-4-[(1-oxido-5-quinolinyl)amino]- (CA INDEX NAME)




RN 852618-50-9 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-phenyl-4-(thieno[2,3-c]pyridin-3-ylamino)- (CA INDEX NAME)




RN 852618-51-0 CAPLUS

CN 4-Pyridazinecarbonitrile, 1-ethyl-1,6-dihydro-6-oxo-3-phenyl-5-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-52-1 CAPLUS

CN 4-Pyridazinecarbonitrile, 1-ethyl-1,6-dihydro-3-(3-methylphenyl)-6-oxo-5-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-53-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-(1-hydroxyethyl)-6-phenyl-4-(5-quinolinylamino)- (CA INDEX NAME)



RN 852618-54-3 CAPLUS


CN 3(2H)-Pyridazinone, 2-ethyl-6-(4-methylphenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)



RN 852618-55-4 CAPLUS


CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-6-(4-methylphenyl)-

(CA INDEX NAME)




RN 852618-56-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(4-methylphenyl)-4-[(4-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 852618-57-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(3-methylphenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-58-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-6-(3-methylphenyl)- (CA INDEX NAME)




RN 852618-59-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(3-methylphenyl)-4-[(4-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 852618-60-1 CAPLUS

CN Benzoic acid, 4-[[2-ethyl-2,3-dihydro-6-(3-methylphenyl)-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 852618-61-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(5-methyl-3-pyridinyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-62-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-6-(5-methyl-3-pyridinyl)- (CA INDEX NAME)




RN 852618-63-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(5-methyl-3-pyridinyl)-4-[(4-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 852618-64-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(1,7-naphthyridin-5-ylamino)-6-phenyl- (CA INDEX NAME)




RN 852618-65-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-[(acetyloxy)methyl]-2-ethyl-6-phenyl-4-(3-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 852618-66-7 CAPLUS

CN Butanoic acid, [1-ethyl-1,6-dihydro-6-oxo-3-phenyl-5-(3-pyridinylamino)-4-pyridazinyl]methyl ester (CA INDEX NAME)




RN 852618-67-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-[2-(4-methoxyphenyl)-4-thiazolyl]-6-phenyl-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-68-9 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-6-(6-methyl-3-pyridinyl)- (CA INDEX NAME)




RN 852618-69-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-(6-methyl-3-pyridinyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-70-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-[2-(4-methoxyphenyl)-4-thiazolyl]-4-[(4-methyl-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 852618-71-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-6-phenyl-4-(3-pyridinylamino)-5-[2-(4-pyridinyl)-4-thiazolyl]- (CA INDEX NAME)




RN 852618-72-5 CAPLUS

CN 2-Thiazolecarboxylic acid, 4-[1-ethyl-1,6-dihydro-6-oxo-3-phenyl-5-(3-pyridinylamino)-4-pyridazinyl]-, ethyl ester (CA INDEX NAME)




RN 852618-73-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-5-[2-(4-methoxyphenyl)-4-thiazolyl]-6-phenyl- (CA INDEX NAME)




RN 852618-74-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(4-methyl-3-pyridinyl)amino]-6-phenyl-5-[2-(4-pyridinyl)-4-thiazolyl]- (CA INDEX NAME)




RN 852618-75-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-[2-(4-chlorophenyl)-4-thiazolyl]-2-ethyl-4-[(4-methyl-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 852618-76-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-[2-(4-chlorophenyl)-4-thiazolyl]-2-ethyl-6-phenyl-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 852618-77-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-[2-(4-chlorophenyl)-4-thiazolyl]-2-ethyl-4-(4-isoquinolinylamino)-6-phenyl- (CA INDEX NAME)




RN 852618-78-1 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(4-methyl-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 852618-79-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(4-methyl-1-oxido-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)



RN 852618-80-5 CAPLUS

CN Benzoic acid, 4-[(2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, ethyl ester (CA INDEX NAME)




IT 627495-22-1P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 720716-40-5P, 5-Acetyl-2-ethyl-6-phenyl-4-((quinolin-5-yl)amino)pyridazin-3(2H)-one 852617-64-2P, 6-Phenyl-4-phenylamino-2H-pyridazin-3-one 852617-75-5P, 4-((2-Ethyl-3-oxo-6-m-tolyl-2,3-dihydropyridazin-4-yl)amino)benzoic acid methyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridazin-3(2H)-ones and their use as PDE4 inhibitors)


RN 627495-22-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720716-40-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 852617-64-2 CAPLUS

CN 3(2H)-Pyridazinone, 6-phenyl-4-(phenylamino)- (CA INDEX NAME)



RN 852617-75-5 CAPLUS

CN Benzoic acid, 4-[[2-ethyl-2,3-dihydro-6-(3-methylphenyl)-3-oxo-4-pyridazinyl]amino]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:565225 CAPLUS Full-text
DOCUMENT NUMBER: 141:106481
TITLE: Preparation of pyridazin-3(2H)-ones as
Phosphodiesterase 4 (PDE4) inhibitors
INVENTOR(S): Dal Piaz, Vittorio; Aguilar Izquierdo, Nuria; Buil
Albero Maria, Antonia; Carrascal Riera, Marta; Gracia
Ferrer, Jordi; Giovannoni, Maria Paola; Vergelli,
Claudia
PATENT ASSIGNEE(S): Almirall Prodesfarma Sa, Spain
SOURCE: PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058729	A1	20040715	WO 2003-EP14722	20031222 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2211344	A1	20040701	ES 2002-3003	20021226 <--
ES 2211344	B1	20051001		
CA 2512099	A1	20040715	CA 2003-2512099	20031222 <--
AU 2003290110	A1	20040722	AU 2003-290110	20031222 <--
EP 1575926	A1	20050921	EP 2003-782471	20031222 <--
EP 1575926	B1	20080305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016883	A	20051025	BR 2003-16883	20031222 <--
CN 1753876	A	20060329	CN 2003-80109897	20031222 <--
JP 2006515302	T	20060525	JP 2004-562819	20031222 <--
ZA 2005004943	A	20060830	ZA 2005-4943	20031222 <--
MX 2005PA06809	A	20050908	MX 2005-PA6809	20050621 <--
IN 2005CN01395	A	20070907	IN 2005-CN1395	20050624 <--
NO 2005003614	A	20050926	NO 2005-3614	20050725 <--
US 2006173008	A1	20060803	US 2005-539821	20051214 <--
PRIORITY APPLN. INFO.:			ES 2002-3003	A 20021226 <--
			WO 2003-EP14722	W 20031222 <--
OTHER SOURCE(S):		MARPAT 141:106481		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [wherein R1, R2 = independently H, acyl, hydroxycarbonyl, alkoxy carbonyl, monoalkyl/dialkyl/carbamoyl, (un)substituted alk(en/yn)yl, hetero/aryl, (un)saturated heterocyclyl, etc.; R3 = (un)substituted monocyclic or polycyclic hetero/aryl; R5 = (un)substituted alkoxy carbonyl, monocyclic or polycyclic hetero/aryl; R4 = H, OH and derivs., NH2 and derivs., (un)substituted alk(en/yn)yl, etc.; and their N-oxides and pharmaceutically acceptable salts] were prepared as potent and selective inhibitors of Phosphodiesterase 4 (PDE4). Four pharmaceutical compns. are given. For example, II was prepared by hydrogenation of 5-acetyl-4-amino-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one over Pd/C in ethanol, and reaction of the amine with 3-fluorophenylboronic acid in the presence of Cu(OAc)2/TEA/mol. sieves/CH2Cl2. Preferred I exhibited an IC50 value < 30 nM for the inhibition of PDE4. I and their pharmaceutical compns. are useful for prevention and treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease (no data).
- IT 720715-59-3P, 5-Acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-60-6P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-61-7P, 5-Acetyl-4-[(3,5-dichlorophenyl)amino]-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-62-8P, 5-Acetyl-2-ethyl-4-(1-naphthylamino)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-63-9P, Methyl 4-[[5-acetyl-2-ethyl-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazin-4-yl]amino]benzoate 720715-64-0P, 5-Acetyl-2-ethyl-4-[(2-fluorophenyl)amino]-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-65-1P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-66-2P, 5-Acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-67-3P, 3-[[5-Acetyl-2-ethyl-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720715-68-4P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-69-5P, 5-Acetyl-2-(cyclopropylmethyl)-4-[(3,5-dichlorophenyl)amino]-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-70-8P, 5-Acetyl-2-(cyclopropylmethyl)-4-[(2-fluorophenyl)amino]-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-71-9P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-72-0P, 3-[[5-Acetyl-2-(cyclopropylmethyl)-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720715-73-1P, Methyl 4-[[5-acetyl-2-(2-hydroxyethyl)-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazin-4-yl]amino]benzoate 720715-74-2P, 5-Acetyl-4-[(2-fluorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-75-3P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-76-4P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720715-77-5P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(pyridin-2-yl)pyridazin-3(2H)-one 720715-78-6P, 3-[[5-Acetyl-2-ethyl-3-oxo-6-(pyridin-2-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720715-79-7P, 5-Acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(pyridin-2-yl)pyridazin-3(2H)-one 720715-80-0P, 3-[[5-Acetyl-2-(cyclopropylmethyl)-3-oxo-6-(pyridin-2-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720715-81-1P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(pyridin-2-yl)pyridazin-3(2H)-one 720715-82-2P, 5-Acetyl-2-(cyclopropylmethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-(pyridin-2-yl)pyridazin-3(2H)-one 720715-83-3P, 5-Acetyl-2-(cyclopropylmethyl)-4-[(3,5-dichlorophenyl)amino]-6-(pyridin-2-yl)pyridazin-3(2H)-one 720715-84-4P, 3-[[5-Acetyl-2-(2-hydroxyethyl)-3-oxo-6-(pyridin-2-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720715-85-5P,

5-Acetyl-4-[(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-2-yl)pyridazin-3(2H)-one 720715-86-6P, 5-Acetyl-4-[(3,5-dichlorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-2-yl)pyridazin-3(2H)-one 720715-87-7P, 5-Acetyl-2-(2-hydroxyethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-(pyridin-2-yl)pyridazin-3(2H)-one 720715-88-8P, 5-Acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-89-9P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-90-2P, 5-Acetyl-2-ethyl-4-(1-naphthylamino)-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-91-3P, 5-Acetyl-2-ethyl-4-[(2-methylphenyl)amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-92-4P, Methyl 4-[[5-acetyl-2-ethyl-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]amino]benzoate 720715-93-5P, 5-Acetyl-2-ethyl-4-[(2-methoxyphenyl)amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-94-6P, 5-Acetyl-2-ethyl-4-[(3-methoxyphenyl)amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-95-7P, 5-Acetyl-2-ethyl-4-[(2-fluorophenyl)amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-96-8P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-97-9P, 3-[[5-Acetyl-2-ethyl-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720715-98-0P, 5-Acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720715-99-1P, 4-[[5-Acetyl-2-ethyl-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]amino]benzoic acid 720716-00-7P, 5-Acetyl-2-(cyclopropylmethyl)-4-[(2-fluorophenyl)amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-01-8P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-02-9P, 3-[[5-Acetyl-2-(cyclopropylmethyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720716-03-0P, 5-Acetyl-2-(cyclopropylmethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-04-1P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-05-2P, 5-Acetyl-4-[(2-fluorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-06-3P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-07-4P, 3-[[5-Acetyl-2-(2-hydroxyethyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720716-08-5P, 5-Acetyl-2-(2-hydroxyethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-09-6P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-10-9P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(thien-2-yl)pyridazin-3(2H)-one 720716-11-0P, 5-Acetyl-4-[bis(3-fluorophenyl)amino]-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one 720716-12-1P, 5-Acetyl-4-[bis(4-methoxycarbonylphenyl)amino]-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one 720716-13-2P, 5-Acetyl-4-[bis[4-(hydroxymethyl)phenyl]amino]-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one 720716-14-3P, 5-Acetyl-4-[bis(3-nitrophenyl)amino]-2-ethyl-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-15-4P, 5-Acetyl-4-[bis(3-fluorophenyl)amino]-2-ethyl-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-16-5P, 5-Acetyl-4-[bis(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720716-17-6P, 5-Acetyl-4-[bis(3,5-dichlorophenyl)amino]-2-(cyclopropylmethyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720716-18-7P, 5-Acetyl-4-[bis(4-methoxycarbonylphenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720716-19-8P, 5-Acetyl-4-[bis(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(pyridin-2-yl)pyridazin-3(2H)-one 720716-20-1P, 5-Acetyl-4-[bis(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(pyridin-4-

yl)pyridazin-3(2H)-one 720716-21-2P, 5-Acetyl-2-ethyl-6-phenyl-4-(pyridin-3-ylamino)pyridazin-3(2H)-one 720716-22-3P, 5-Acetyl-4-[(3,5-dichloropyridin-4-yl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 720716-23-4P, 5-Acetyl-2-ethyl-6-phenyl-4-(pyrazin-2-ylamino)pyridazin-3(2H)-one 720716-24-5P, 5-Acetyl-2-ethyl-6-phenyl-4-(pyrimidin-2-ylamino)pyridazin-3(2H)-one 720716-25-6P, 5-Acetyl-2-ethyl-6-phenyl-4-(quinolin-8-ylamino)pyridazin-3(2H)-one 720716-26-7P, 5-Acetyl-2-ethyl-4-[(5-nitropyridin-2-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-27-8P, 5-Acetyl-2-ethyl-4-(1H-indol-4-ylamino)-6-phenylpyridazin-3(2H)-one 720716-28-9P, 5-Acetyl-4-(1,3-benzothiazol-6-ylamino)-2-ethyl-6-phenylpyridazin-3(2H)-one 720716-29-0P, 5-Acetyl-2-ethyl-6-phenyl-4-(thianthren-1-ylamino)pyridazin-3(2H)-one 720716-30-3P, Methyl 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]thiophene-2-carboxylate 720716-31-4P, 5-Acetyl-2-ethyl-4-[(4-methylpyridin-2-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-32-5P, 5-Acetyl-2-ethyl-6-phenyl-4-(1H-1,2,4-triazol-5-ylamino)pyridazin-3(2H)-one 720716-33-6P, 5-Acetyl-2-ethyl-4-[(6-methoxypyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-34-7P, 5-Acetyl-2-ethyl-4-(2H-indazol-5-ylamino)-6-phenylpyridazin-3(2H)-one 720716-35-8P, Methyl 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]thiophene-3-carboxylate 720716-36-9P, 5-Acetyl-2-ethyl-6-phenyl-4-(pyridin-2-ylamino)pyridazin-3(2H)-one 720716-37-0P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]thiophene-2-carboxylic acid 720716-38-1P, 5-Acetyl-2-ethyl-4-[(3-methylcinnolin-5-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-39-2P, 5-Acetyl-2-ethyl-4-[(2-methylquinolin-8-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-40-5P, 5-Acetyl-2-ethyl-6-phenyl-4-(quinolin-5-ylamino)pyridazin-3(2H)-one 720716-41-6P, 5-Acetyl-2-ethyl-4-(1H-indol-5-ylamino)-6-phenylpyridazin-3(2H)-one 720716-42-7P, 5-Acetyl-2-ethyl-4-(isoquinolin-5-ylamino)-6-phenylpyridazin-3(2H)-one 720716-43-8P, 5-Acetyl-2-ethyl-4-[(6-methoxyquinolin-8-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-44-9P, 5-Acetyl-4-[(5-bromoquinolin-8-yl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 720716-45-0P, 5-Acetyl-2-ethyl-4-[(4-methylpyrimidin-2-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-46-1P, 5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-47-2P, 5-Acetyl-6-(3-chlorophenyl)-2-cyclopropylmethyl-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-48-3P, 5-Acetyl-2-ethyl-6-(3-fluorophenyl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-49-4P, 5-Acetyl-6-(3-fluorophenyl)-2-isopropyl-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-50-7P, 5-Acetyl-2-cyclopropylmethyl-6-(3-fluorophenyl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-51-8P, 5-Acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-52-9P, 5-Acetyl-6-(1H-benzimidazol-2-yl)-4-(3-chlorophenylamino)-2-ethyl-2H-pyridazin-3-one 720716-53-0P, 5-Acetyl-6-(benzoxazol-2-yl)-4-(3-chlorophenylamino)-2-ethylpyridazin-3(2H)-one 720716-54-1P, 5-Acetyl-6-(1,3-benzoxazol-2-yl)-2-ethyl-4-[(3-fluorophenyl)amino]pyridazin-3(2H)-one 720716-55-2P, 5-Acetyl-6-(benzoxazol-2-yl)-4-[bis(3-chlorophenyl)amino]-2-ethylpyridazin-3(2H)-one 720716-56-3P, 5-Acetyl-6-(benzoxazol-2-yl)-4-[bis(3-fluorophenyl)amino]-2-ethylpyridazin-3(2H)-one 720716-57-4P, 5-Acetyl-6-(1,3-benzoxazol-2-yl)-2-ethyl-4-[(3-methoxyphenyl)amino]pyridazin-3(2H)-one 720716-58-5P, 5-Acetyl-6-(1,3-benzoxazol-2-yl)-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]pyridazin-3(2H)-one 720716-59-6P, 5-Acetyl-2-ethyl-4-(isoquinolin-4-ylamino)-6-phenylpyridazin-3(2H)-one

720716-60-9P, 5-Acetyl-2-ethyl-4-(1,6-naphthyridin-8-ylamino)-6-phenylpyridazin-3(2H)-one 720716-61-0P, 5-Acetyl-2-ethyl-4-[(5-methoxypyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-62-1P, 5-Acetyl-2-ethyl-6-(pyridin-4-yl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-63-2P, 5-Acetyl-2-ethyl-4-[(4-methylpyridin-3-yl)amino]-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-64-3P, 5-Acetyl-2-ethyl-4-(isoquinolin-4-ylamino)-6-(pyridin-4-yl)pyridazin-3(2H)-one 720716-65-4P, 5-Acetyl-2-ethyl-6-(pyridin-4-yl)-4-[(3,4,5-trifluorophenyl)amino]pyridazin-3(2H)-one 720716-66-5P, 5-Acetyl-2-ethyl-4-[(4-methylpyridin-3-yl)amino]-6-(pyridin-3-yl)pyridazin-3(2H)-one 720716-67-6P, 5-Acetyl-2-ethyl-4-(isoquinolin-4-ylamino)-6-(pyridin-3-yl)pyridazin-3(2H)-one 720716-68-7P, 5-Acetyl-2-ethyl-6-(pyridin-3-yl)-4-[(3,4,5-trifluorophenyl)amino]pyridazin-3(2H)-one 720716-69-8P, 5-Acetyl-2-ethyl-4-(quinolin-5-ylamino)-6-(thien-2-yl)pyridazin-3(2H)-one 720716-70-1P, 5-Acetyl-2-ethyl-4-(pyridin-3-ylamino)-6-(thien-2-yl)pyridazin-3(2H)-one 720716-71-2P, 4-[[5-Acetyl-2-ethyl-3-oxo-6-(thien-2-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720716-72-3P, 5-Acetyl-2-ethyl-6-(thien-2-yl)-4-[(3,4,5-trifluorophenyl)amino]pyridazin-3(2H)-one 720716-73-4P, 5-Acetyl-4-[bis(4-cyanophenyl)amino]-2-ethyl-6-(thien-2-yl)pyridazin-3(2H)-one 720716-74-5P, 5-Acetyl-2-(cyclopropylmethyl)-4-(quinolin-5-ylamino)-6-(thien-2-yl)pyridazin-3(2H)-one 720716-75-6P, 5-Acetyl-2-(cyclopropylmethyl)-4-(pyridin-3-ylamino)-6-(thien-2-yl)pyridazin-3(2H)-one 720716-76-7P, 5-Acetyl-2-ethyl-4-(quinolin-5-ylamino)-6-(thien-3-yl)pyridazin-3(2H)-one 720716-77-8P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(thien-3-yl)pyridazin-3(2H)-one 720716-78-9P, 5-Acetyl-2-ethyl-4-(pyridin-3-ylamino)-6-(thien-3-yl)pyridazin-3(2H)-one 720716-79-0P, 4-[[5-Acetyl-2-ethyl-3-oxo-6-(thien-3-yl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 720716-80-3P, 5-Acetyl-2-ethyl-6-(thien-3-yl)-4-[(3,4,5-trifluorophenyl)amino]pyridazin-3(2H)-one 720716-81-4P, 2-Ethyl-6-phenyl-5-(3-phenylpropanoyl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720716-82-5P, 2-Ethyl-6-phenyl-5-(3-phenylpropanoyl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-83-6P, 2-Ethyl-4-(isoquinolin-4-ylamino)-6-phenyl-5-(3-phenylpropanoyl)pyridazin-3(2H)-one 720716-84-7P, 2-Ethyl-6-phenyl-4-(quinolin-5-ylamino)-5-[3-(thien-3-yl)propanoyl]pyridazin-3(2H)-one 720716-85-8P, 2-Ethyl-6-phenyl-4-(pyridin-3-ylamino)-5-[3-(thien-3-yl)propanoyl]pyridazin-3(2H)-one 720716-86-9P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(1H-imidazo[4,5-b]pyridin-2-yl)pyridazin-3(2H)-one 720716-87-0P, 5-Acetyl-6-(1,3-benzothiazol-2-yl)-4-[(3-chlorophenyl)amino]-2-ethylpyridazin-3(2H)-one 720716-88-1P, 5-Acetyl-6-(benzo[b]furan-2-yl)-4-[(3-chlorophenyl)amino]-2-ethylpyridazin-3(2H)-one 720716-89-2P, 5-Acetyl-2-ethyl-6-(pyridin-3-yl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-90-5P, 4-[[5-Acetyl-2-ethyl-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazin-4-yl]amino]benzoic acid 720716-91-6P, 5-Acetyl-2-ethyl-4-[(1-oxidopyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-92-7P, Ethyl 3-[5-acetyl-2-ethyl-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-ylamino]benzoate 720716-93-8P, 3-[[5-Acetyl-2-ethyl-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]amino]benzamide 720716-94-9P, 5-Acetyl-2-ethyl-6-phenyl-4-[(thieno[2,3-b]pyridin-3-yl)amino]pyridazin-3(2H)-one 720716-95-0P, 5-Acetyl-2-ethyl-4-[(6-fluoropyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-96-1P, 5-Acetyl-2-ethyl-4-[(2-methylpyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one 720716-97-2P, 5-Acetyl-4-[[2-(dimethylamino)pyridin-3-yl]amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 720716-98-3P, 5-[[5-Acetyl-2-ethyl-3-

oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]pyridine-2-carboxylic acid
 720716-99-4P, 5-Acetyl-2-ethyl-4-[(2-methoxypyridin-3-yl)amino]-6-
 phenylpyridazin-3(2H)-one 720717-00-0P, 5-Acetyl-2-ethyl-4-(1H-
 indazol-4-ylamino)-6-phenylpyridazin-3(2H)-one 720717-01-1P,
 5-Acetyl-4-[(2-chloropyridin-3-yl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-
 one 720717-02-2P, 5-Acetyl-4-[(5-chloropyridin-3-yl)amino]-2-
 ethyl-6-phenylpyridazin-3(2H)-one 720717-03-3P,
 5-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-
 yl)amino]nicotinamide 720717-04-4P, 5-Acetyl-2-ethyl-4-(1,7-
 naphthyridin-8-ylamino)-6-phenylpyridazin-3(2H)-one 720717-05-5P
 720717-06-6P 720717-07-7P, 5-[(5-Acetyl-2-ethyl-3-oxo-6-
 phenyl-2,3-dihydropyridazin-4-yl)amino]nicotinic acid 720717-08-8P
 , 5-Acetyl-2-ethyl-4-(1,5-naphthyridin-3-ylamino)-6-phenylpyridazin-3(2H)-
 one 720717-09-9P, 5-Acetyl-2-ethyl-4-[(8-hydroxy-2,7-
 naphthyridin-5-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-10-2P
 , 5-Acetyl-2-ethyl-6-phenyl-4-(thien-2-ylamino)pyridazin-3(2H)-one
 720717-11-3P, 5-Acetyl-2-ethyl-6-phenyl-4-[(2-phenylpyridin-3-
 yl)amino]pyridazin-3(2H)-one 720717-12-4P, Ethyl
 2-[5-[(5-acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-
 yl)amino]pyridin-2-yl]acetate 720717-13-5P, 5-Acetyl-2-ethyl-4-
 [(6-methylpyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one
 720717-14-6P, 5-Acetyl-2-ethyl-4-[(6-hydroxypyridin-3-yl)amino]-6-
 phenylpyridazin-3(2H)-one 720717-15-7P, 5-Acetyl-2-ethyl-4-[(2-
 fluoropyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-16-8P
 , 5-Acetyl-4-[(6-chloro-4-methylpyridin-3-yl)amino]-2-ethyl-6-
 phenylpyridazin-3(2H)-one 720717-17-9P, 5-Acetyl-2-ethyl-4-[(3-
 hydroxypyridin-2-yl)amino]-6-phenylpyridazin-3(2H)-one
 720717-18-0P, 5-Acetyl-2-ethyl-4-[(4-methoxypyridin-3-yl)amino]-6-
 phenylpyridazin-3(2H)-one 720717-19-1P, 5-Acetyl-2-ethyl-4-
 (isoquinolin-8-ylamino)-6-phenylpyridazin-3(2H)-one 720717-20-4P
 , 5-Acetyl-2-ethyl-6-phenyl-4-(quinolin-7-ylamino)pyridazin-3(2H)-one
 720717-21-5P, 5-Acetyl-4-[(5-chloropyridin-3-yl)amino]-2-ethyl-6-
 (3-fluorophenyl)pyridazin-3(2H)-one 720717-22-6P,
 5-Acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(2-methoxypyridin-3-
 yl)amino]pyridazin-3(2H)-one 720717-23-7P, 5-Acetyl-2-ethyl-6-(4-
 fluorophenyl)-4-[(2-methylpyridin-3-yl)amino]pyridazin-3(2H)-one
 720717-24-8P, 5-Acetyl-4-[(2-chloropyridin-3-yl)amino]-2-ethyl-6-
 (4-fluorophenyl)pyridazin-3(2H)-one 720717-25-9P,
 5-Acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(4-methylpyridin-3-
 yl)amino]pyridazin-3(2H)-one 720717-26-0P, 5-Acetyl-2-ethyl-6-(4-
 fluorophenyl)-4-[(2-fluoropyridin-3-yl)amino]pyridazin-3(2H)-one
 720717-27-1P, 5-Acetyl-4-[(2-chloropyridin-3-yl)amino]-2-
 (cyclopropylmethyl)-6-(4-fluorophenyl)pyridazin-3(2H)-one
 720717-28-2P, 5-Acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-
 [(2-methoxypyridin-3-yl)amino]pyridazin-3(2H)-one 720717-29-3P,
 5-Acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-[(2-methylpyridin-3-
 yl)amino]pyridazin-3(2H)-one 720717-30-6P, 5-Acetyl-2-
 (cyclopropylmethyl)-6-(4-fluorophenyl)-4-[(2-fluoropyridin-3-
 yl)amino]pyridazin-3(2H)-one 720717-31-7P
 , 5-Acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-[(4-methylpyridin-3-
 yl)amino]pyridazin-3(2H)-one 720717-32-8P, 5-Acetyl-2-
 (cyclopropylmethyl)-6-(4-fluorophenyl)-4-[(pyridin-3-yl)amino]pyridazin-
 3(2H)-one 720717-33-9P, 5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-
 [(2-methylpyridin-3-yl)amino]pyridazin-3(2H)-one 720717-34-0P,
 5-Acetyl-6-(3-chlorophenyl)-4-[(2-chloropyridin-3-yl)amino]-2-
 ethylpyridazin-3(2H)-one 720717-35-1P, 5-Acetyl-6-(3-
 chlorophenyl)-2-ethyl-4-[(4-methylpyridin-3-yl)amino]pyridazin-3(2H)-one
 720717-36-2P, Ethyl 5-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-
 dihydropyridazin-4-yl)amino]quinoline-8-carboxylate 720717-37-3P
 , 5-Acetyl-2-ethyl-4-[(4-methylpyridin-3-yl)amino]-6-phenylpyridazin-3(2H)-

one 720717-38-4P, 5-Acetyl-2-ethyl-4-(isoquinolin-4-ylamino)-6-(4-methoxyphenyl)pyridazin-3(2H)-one 720717-39-5P, 5-Acetyl-2-ethyl-6-(4-methoxyphenyl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720717-40-8P, 5-Acetyl-2-ethyl-6-(4-methoxyphenyl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-41-9P, 5-Acetyl-2-ethyl-6-(4-methoxyphenyl)-4-[(1-oxoquinolin-5-yl)amino]-1-pyridazin-3(2H)-one 720717-42-0P, 5-Acetyl-2-ethyl-4-(isoquinolin-4-ylamino)-6-(3-methoxyphenyl)pyridazin-3(2H)-one 720717-43-1P, 5-Acetyl-2-ethyl-6-(3-methoxyphenyl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720717-44-2P, 5-Acetyl-2-ethyl-6-(3-methoxyphenyl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-45-3P, 5-Acetyl-2-ethyl-6-(3-methoxyphenyl)-4-[(1-oxidoquinolin-5-yl)amino]pyridazin-3(2H)-one 720717-46-4P, 5-Acetyl-2-ethyl-4-(isoquinolin-4-ylamino)-6-(4-methylphenyl)pyridazin-3(2H)-one 720717-47-5P, 5-Acetyl-2-ethyl-6-(4-methylphenyl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720717-48-6P, 5-Acetyl-2-ethyl-6-(4-methylphenyl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-49-7P, 5-Acetyl-2-ethyl-6-(4-methylphenyl)-4-[(1-oxidoquinolin-5-yl)amino]pyridazin-3(2H)-one 720717-50-0P, 5-Acetyl-2-ethyl-6-(4-methylphenyl)-4-[(4-methylpyridin-3-yl)amino]pyridazin-3(2H)-one 720717-51-1P, 5-Acetyl-2-ethyl-4-(isoquinolin-4-ylamino)-6-(3-methylphenyl)pyridazin-3(2H)-one 720717-52-2P, 5-Acetyl-2-ethyl-6-(3-methylphenyl)-4-[(pyridin-3-yl)amino]pyridazin-3(2H)-one 720717-53-3P, 5-Acetyl-2-ethyl-6-(3-methylphenyl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-54-4P, 5-Acetyl-2-ethyl-6-(3-methylphenyl)-4-[(4-methylpyridin-3-yl)amino]pyridazin-3(2H)-one 720717-55-5P, Methyl 4-[4-Acetyl-1-ethyl-5-(isoquinolin-4-ylamino)-6-oxo-1,6-dihydropyridazin-3-yl]benzoate 720717-56-6P, Methyl 4-[4-Acetyl-1-ethyl-6-oxo-5-(pyridin-3-ylamino)-1,6-dihydropyridazin-3-yl]benzoate 720717-57-7P, 4-[4-Acetyl-1-ethyl-6-oxo-5-(pyridin-3-ylamino)-1,6-dihydropyridazin-3-yl]benzoic acid 720717-58-8P, Methyl 4-[4-acetyl-1-ethyl-5-[(4-methylpyridin-3-yl)amino]-6-oxo-1,6-dihydropyridazin-3-yl]benzoate 720717-59-9P, 4-[4-Acetyl-1-ethyl-5-[(4-methylpyridin-3-yl)amino]-6-oxo-1,6-dihydropyridazin-3-yl]benzoic acid 720717-60-2P, Methyl 3-[4-acetyl-1-ethyl-6-oxo-5-(pyridin-3-ylamino)-1,6-dihydropyridazin-3-yl]benzoate 720717-61-3P, 3-[4-Acetyl-1-ethyl-6-oxo-5-(pyridin-3-ylamino)-1,6-dihydropyridazin-3-yl]benzoic acid 720717-62-4P, 5-Acetyl-4-[(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-(pyridin-4-yl)pyridazin-3(2H)-one 720717-63-5P, 5-Acetyl-4-[bis(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-(pyridin-4-yl)pyridazin-3(2H)-one 720717-64-6P, 5-Acetyl-4-[(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one 720717-65-7P, 5-Acetyl-4-[bis(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-(pyridin-3-yl)pyridazin-3(2H)-one 720717-66-8P 720717-67-9P 720717-68-0P, 5-Acetyl-2-ethyl-4-[(3-methylpyridin-2-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-69-1P, 5-Acetyl-2-ethyl-6-phenyl-4-(1H-pyrazol-3-ylamino)pyridazin-3(2H)-one 720717-70-4P, 5-Acetyl-2-ethyl-6-phenyl-4-(9H-purin-6-ylamino)pyridazin-3(2H)-one 720717-71-5P, 5-Acetyl-2-ethyl-4-[(3-methylisoxazol-5-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-72-6P, 5-Acetyl-2-ethyl-4-[(8-hydroxyquinolin-5-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-73-7P, 5-Acetyl-2-ethyl-4-(1H-indazol-7-ylamino)-6-phenylpyridazin-3(2H)-one 720717-74-8P, 5-Acetyl-4-[(6-bromoquinolin-8-yl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 720717-75-9P, 5-Acetyl-2-ethyl-4-[(5-methylisoxazol-3-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-76-0P, 5-Acetyl-2-ethyl-4-(isoxazol-3-ylamino)-6-phenylpyridazin-3(2H)-one 720717-77-1P, 5-Acetyl-2-(cyclopropylmethyl)-6-phenyl-4-(quinolin-5-ylamino)pyridazin-


3(2H)-one 720717-78-2P, 5-Acetyl-2-(cyclopropylmethyl)-6-phenyl-4-(quinolin-8-ylamino)pyridazin-3(2H)-one 720717-79-3P, 5-Acetyl-2-ethyl-4-[(1-methyl-1H-pyrazol-3-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-80-6P, 5-Acetyl-2-ethyl-4-[(1-oxidoquinolin-5-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-81-7P, 5-Acetyl-2-ethyl-4-[(2-oxidoisoquinolin-5-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-82-8P, 5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-83-9P, 5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(quinolin-8-yl)amino]pyridazin-3(2H)-one 720717-84-0P, 5-Acetyl-2-ethyl-6-(pyridin-4-yl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-85-1P, 5-Acetyl-2-ethyl-6-(pyridin-3-yl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-86-2P, 5-Acetyl-2-ethyl-4-[(8-fluoroquinolin-5-yl)amino]-6-phenylpyridazin-3(2H)-one 720717-87-3P, 5-Acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-[(quinolin-8-yl)amino]pyridazin-3(2H)-one 720717-88-4P, 5-Acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-89-5P, 5-Acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(quinolin-8-yl)amino]pyridazin-3(2H)-one 720717-90-6P, 5-Acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-91-9P, 5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(1-oxidoquinolin-5-yl)amino]pyridazin-3(2H)-one 720717-92-0P, 5-Acetyl-2-ethyl-4-[(2-methylquinolin-5-yl)amino]-6-phenylpyridazin-3(2H)-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4 inhibitor; preparation of pyridazinones as PDE4 inhibitors)


RN 720715-59-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-60-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-61-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-dichlorophenyl)amino]-2-ethyl-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-62-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1-naphthalenylamino)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-63-9 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]amino]-, methyl ester (CA INDEX NAME)




RN 720715-64-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-fluorophenyl)amino]-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-65-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-66-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-67-3 CAPLUS

CN Benzonitrile, 3-[[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720715-68-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-69-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[(3,5-dichlorophenyl)amino]-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-70-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[(2-fluorophenyl)amino]-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-71-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-72-0 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2-(cyclopropylmethyl)-2,3-dihydro-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720715-73-1 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2-(cyclopropylmethyl)-2,3-dihydro-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]amino]-, methyl ester (CA INDEX NAME)




RN 720715-74-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-fluorophenyl)amino]-2-(2-hydroxyethyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-75-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-76-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720715-77-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720715-78-6 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(2-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720715-79-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720715-80-0 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2-(cyclopropylmethyl)-2,3-dihydro-3-oxo-6-(2-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720715-81-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720715-82-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720715-83-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[(3,5-dichlorophenyl)amino]-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720715-84-4 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2,3-dihydro-2-(2-hydroxyethyl)-3-oxo-6-(2-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720715-85-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720715-86-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-dichlorophenyl)amino]-2-(2-hydroxyethyl)-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720715-87-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(2-hydroxyethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720715-88-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-89-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-90-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1-naphthalenylamino)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-91-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methylphenyl)amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-92-4 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinyl]amino]-, methyl ester (CA INDEX NAME)




RN 720715-93-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methoxyphenyl)amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-94-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-methoxyphenyl)amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-95-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-fluorophenyl)amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-96-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-97-9 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720715-98-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720715-99-1 CAPLUS

CN Benzoic acid, 4-[[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720716-00-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[(2-fluorophenyl)amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-01-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-02-9 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2-(cyclopropylmethyl)-2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720716-03-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-04-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-05-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-fluorophenyl)amino]-2-(2-hydroxyethyl)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-07-4 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2,3-dihydro-2-(2-hydroxyethyl)-3-oxo-6-(4-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720716-08-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(2-hydroxyethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-09-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-10-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(2-thienyl)- (CA INDEX NAME)




RN 720716-11-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-fluorophenyl)amino]-2-ethyl-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720716-12-1 CAPLUS

CN Benzoic acid, 4,4'-[[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]imino]bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 720716-13-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis[4-(hydroxymethyl)phenyl]amino]-2-ethyl-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720716-14-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-nitrophenyl)amino]-2-ethyl-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-15-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-fluorophenyl)amino]-2-ethyl-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-16-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720716-17-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3,5-dichlorophenyl)amino]-2-(cyclopropylmethyl)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720716-18-7 CAPLUS

CN Benzoic acid, 4,4'-[[5-acetyl-2,3-dihydro-2-(2-hydroxyethyl)-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]imino]bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 720716-19-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-(2-pyridinyl)- (CA INDEX NAME)




RN 720716-20-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-21-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-22-3 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-dichloro-4-pyridinyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720716-23-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(pyrazinylamino)- (9CI)
(CA INDEX NAME)

RN 720716-24-5 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(2-pyrimidinylamino)- (CA
INDEX NAME)

RN 720716-25-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(8-quinolinylamino)- (CA
INDEX NAME)


RN 720716-26-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(5-nitro-2-pyridinyl)amino]-6-
phenyl- (CA INDEX NAME)




RN 720716-27-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1H-indol-4-ylamino)-6-phenyl- (CA INDEX NAME)




RN 720716-28-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-(6-benzothiazolylamino)-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720716-29-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(1-thianthrenylamino)- (CA INDEX NAME)




RN 720716-30-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, methyl ester (CA INDEX NAME)




RN 720716-31-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-methyl-2-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-32-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(1H-1,2,4-triazol-3-ylamino)- (9CI) (CA INDEX NAME)




RN 720716-33-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(6-methoxy-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-34-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(2H-indazol-5-ylamino)-6-phenyl-
(CA INDEX NAME)




RN 720716-35-8 CAPLUS

CN 3-Thiophenecarboxylic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, methyl ester (CA INDEX NAME)



RN 720716-36-9 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(2-pyridinylamino)- (CA INDEX NAME)



RN 720716-37-0 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-

phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 720716-38-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-methyl-5-cinnolinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-39-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methyl-8-quinolinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-40-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720716-41-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1H-indol-5-ylamino)-6-phenyl- (CA INDEX NAME)




RN 720716-42-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(5-isoquinolinylamino)-6-phenyl- (CA INDEX NAME)




RN 720716-43-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(6-methoxy-8-quinolinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-44-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(5-bromo-8-quinolinyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720716-45-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-methyl-2-pyrimidinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-46-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-47-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-48-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-fluorophenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-49-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-fluorophenyl)-2-(1-methylethyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-50-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(3-fluorophenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-51-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-52-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(1H-benzimidazol-2-yl)-4-[(3-chlorophenyl)amino]-2-ethyl- (CA INDEX NAME)




RN 720716-53-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(2-benzoxazolyl)-4-[(3-chlorophenyl)amino]-2-ethyl- (CA INDEX NAME)




RN 720716-54-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(2-benzoxazolyl)-2-ethyl-4-[(3-fluorophenyl)amino]- (CA INDEX NAME)




RN 720716-55-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(2-benzoxazolyl)-4-[bis(3-chlorophenyl)amino]-2-ethyl- (CA INDEX NAME)




RN 720716-56-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(2-benzoxazolyl)-4-[bis(3-fluorophenyl)amino]-2-ethyl- (CA INDEX NAME)




RN 720716-57-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(2-benzoxazolyl)-2-ethyl-4-[(3-methoxyphenyl)amino]- (CA INDEX NAME)




RN 720716-58-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(2-benzoxazolyl)-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 720716-59-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(4-isoquinolinylamino)-6-phenyl-
(CA INDEX NAME)




RN 720716-60-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1,6-naphthyridin-8-ylamino)-6-phenyl-
(CA INDEX NAME)




RN 720716-61-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(5-methoxy-3-pyridinyl)amino]-6-phenyl-
(CA INDEX NAME)




RN 720716-62-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-pyridinyl)-4-(3-pyridinylamino)-
(CA INDEX NAME)


RN 720716-63-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-methyl-3-pyridinyl)amino]-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-64-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(4-isoquinolinylamino)-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720716-65-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-pyridinyl)-4-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 720716-66-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-methyl-3-pyridinyl)amino]-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720716-67-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(4-isoquinolinylamino)-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720716-68-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-pyridinyl)-4-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 720716-69-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(5-quinolinylamino)-6-(2-thienyl)-
(CA INDEX NAME)




RN 720716-70-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(3-pyridinylamino)-6-(2-thienyl)-
(CA INDEX NAME)




RN 720716-71-2 CAPLUS

CN Benzonitrile, 4-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(2-thienyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720716-72-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(2-thienyl)-4-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 720716-73-4 CAPLUS

CN Benzonitrile, 4,4'-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(2-thienyl)-4-pyridazinyl]imino]bis- (9CI) (CA INDEX NAME)




RN 720716-74-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-(5-quinolinylamino)-6-(2-thienyl)- (CA INDEX NAME)




RN 720716-75-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-(3-pyridinylamino)-6-(2-thienyl)- (CA INDEX NAME)




RN 720716-76-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(5-quinolinylamino)-6-(3-thienyl)-
(CA INDEX NAME)




RN 720716-77-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(3-thienyl)-
(CA INDEX NAME)




RN 720716-78-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(3-pyridinylamino)-6-(3-thienyl)-
(CA INDEX NAME)




RN 720716-79-0 CAPLUS

CN Benzonitrile, 4-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(3-thienyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720716-80-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-thienyl)-4-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 720716-81-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-(1-oxo-3-phenylpropyl)-6-phenyl-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720716-82-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-(1-oxo-3-phenylpropyl)-6-phenyl-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-83-6 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-(4-isoquinolinylamino)-5-(1-oxo-3-phenylpropyl)-6-phenyl- (CA INDEX NAME)




RN 720716-84-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-[1-oxo-3-(3-thienyl)propyl]-6-phenyl-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720716-85-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-[1-oxo-3-(3-thienyl)propyl]-6-phenyl-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720716-86-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(1H-imidazo[4,5-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 720716-87-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(2-benzothiazolyl)-4-[(3-chlorophenyl)amino]-2-ethyl- (CA INDEX NAME)




RN 720716-88-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(2-benzofuranyl)-4-[(3-chlorophenyl)amino]-2-ethyl- (CA INDEX NAME)




RN 720716-89-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-pyridinyl)-4-(3-pyridinylamino)-
(CA INDEX NAME)




RN 720716-90-5 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720716-91-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(1-oxido-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-92-7 CAPLUS

CN Benzoic acid, 3-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 720716-93-8 CAPLUS

CN Benzamide, 3-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720716-94-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(thieno[2,3-b]pyridin-3-ylamino)- (CA INDEX NAME)




RN 720716-95-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(6-fluoro-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-96-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methyl-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720716-97-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[[2-(dimethylamino)-3-pyridinyl]amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720716-98-3 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 720716-99-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methoxy-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-00-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1H-indazol-4-ylamino)-6-phenyl-
(CA INDEX NAME)




RN 720717-01-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chloro-3-pyridinyl)amino]-2-ethyl-6-
phenyl- (CA INDEX NAME)




RN 720717-02-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(5-chloro-3-pyridinyl)amino]-2-ethyl-6-
phenyl- (CA INDEX NAME)




RN 720717-03-3 CAPLUS

CN 3-Pyridinecarboxamide, 5-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-
pyridazinyl)amino]- (CA INDEX NAME)




RN 720717-04-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1,7-naphthyridin-8-ylamino)-6-phenyl- (CA INDEX NAME)




RN 720717-05-5 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(2-chloro-3-pyridinyl)amino]-2-ethyl-5-(hydroxyacetyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 720717-06-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, methyl ester (CA INDEX NAME)




RN 720717-07-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 720717-08-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1,5-naphthyridin-3-ylamino)-6-phenyl- (CA INDEX NAME)




RN 720717-09-9 CAPLUS

CN 2,7-Naphthyridin-1(2H)-one, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 720717-10-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(2-thienylamino)- (CA INDEX NAME)




RN 720717-11-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-[(2-phenyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-12-4 CAPLUS

CN 2-Pyridineacetic acid, 5-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 720717-13-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(6-methyl-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-14-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(1,6-dihydro-6-oxo-3-pyridinyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720717-15-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-fluoro-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-16-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(6-chloro-4-methyl-3-pyridinyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720717-17-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-hydroxy-2-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-18-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-methoxy-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-19-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(8-isoquinolinylamino)-6-phenyl- (CA INDEX NAME)




RN 720717-20-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(7-quinolinylamino)- (CA INDEX NAME)




RN 720717-21-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(5-chloro-3-pyridinyl)amino]-2-ethyl-6-(3-fluorophenyl)- (CA INDEX NAME)




RN 720717-22-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(2-methoxy-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-23-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(2-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-24-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chloro-3-pyridinyl)amino]-2-ethyl-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 720717-25-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(4-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-26-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(2-fluoro-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-27-1 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chloro-3-pyridinyl)amino]-2-(cyclopropylmethyl)-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 720717-28-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-
[(2-methoxy-3-pyridinyl)amino]- (CA INDEX NAME)

RN 720717-29-3 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-
[(2-methyl-3-pyridinyl)amino]- (CA INDEX NAME)

RN 720717-30-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-
[(2-fluoro-3-pyridinyl)amino]- (CA INDEX NAME)


RN 720717-31-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-
[(4-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-32-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720717-33-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(2-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-34-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-4-[(2-chloro-3-pyridinyl)amino]-2-ethyl- (CA INDEX NAME)




RN 720717-35-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(4-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-36-2 CAPLUS

CN 8-Quinolinecarboxylic acid, 5-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 720717-37-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-methyl-3-pyridinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-38-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(4-isoquinolinylamino)-6-(4-methoxyphenyl)- (CA INDEX NAME)




RN 720717-39-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-methoxyphenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720717-40-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-methoxyphenyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-41-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-methoxyphenyl)-4-[(1-oxido-5-quinolinyl)amino]- (CA INDEX NAME)




RN 720717-42-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(4-isoquinolinylamino)-6-(3-methoxyphenyl)- (CA INDEX NAME)




RN 720717-43-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-methoxyphenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720717-44-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-methoxyphenyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-45-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-methoxyphenyl)-4-[(1-oxido-5-quinolinyl)amino]- (CA INDEX NAME)




RN 720717-46-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(4-isoquinolinylamino)-6-(4-methylphenyl)- (CA INDEX NAME)




RN 720717-47-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-methylphenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720717-48-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-methylphenyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-49-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-methylphenyl)-4-[(1-oxido-5-quinolinyl)amino]- (CA INDEX NAME)




RN 720717-50-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-methylphenyl)-4-[(4-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-51-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(4-isoquinolinylamino)-6-(3-methylphenyl)- (CA INDEX NAME)




RN 720717-52-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-methylphenyl)-4-(3-pyridinylamino)- (CA INDEX NAME)




RN 720717-53-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-methylphenyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-54-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-methylphenyl)-4-[(4-methyl-3-pyridinyl)amino]- (CA INDEX NAME)




RN 720717-55-5 CAPLUS

CN Benzoic acid, 4-[4-acetyl-1-ethyl-1,6-dihydro-5-(4-isoquinolinylamino)-6-oxo-3-pyridazinyl]-, methyl ester (CA INDEX NAME)




RN 720717-56-6 CAPLUS

CN Benzoic acid, 4-[4-acetyl-1-ethyl-1,6-dihydro-6-oxo-5-(3-pyridinylamino)-3-pyridazinyl]-, methyl ester (CA INDEX NAME)




RN 720717-57-7 CAPLUS

CN Benzoic acid, 4-[4-acetyl-1-ethyl-1,6-dihydro-6-oxo-5-(3-pyridinylamino)-3-pyridazinyl]- (CA INDEX NAME)




RN 720717-58-8 CAPLUS

CN Benzoic acid, 4-[4-acetyl-1-ethyl-1,6-dihydro-5-[(4-methyl-3-pyridinyl)amino]-6-oxo-3-pyridazinyl]-, methyl ester (CA INDEX NAME)




RN 720717-59-9 CAPLUS

CN Benzoic acid, 4-[4-acetyl-1-ethyl-1,6-dihydro-5-[(4-methyl-3-pyridinyl)amino]-6-oxo-3-pyridazinyl]- (CA INDEX NAME)




RN 720717-60-2 CAPLUS

CN Benzoic acid, 3-[4-acetyl-1-ethyl-1,6-dihydro-6-oxo-5-(3-pyridinylamino)-3-pyridazinyl]-, methyl ester (CA INDEX NAME)




RN 720717-61-3 CAPLUS

CN Benzoic acid, 3-[4-acetyl-1-ethyl-1,6-dihydro-6-oxo-5-(3-pyridinylamino)-3-pyridazinyl]- (CA INDEX NAME)




RN 720717-62-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720717-63-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-(4-pyridinyl)- (CA INDEX NAME)




RN 720717-64-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720717-65-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-(3-pyridinyl)- (CA INDEX NAME)




RN 720717-66-8 CAPLUS

CN 1(6H)-Pyridazineacetic acid, 4-acetyl-6-oxo-3-phenyl-5-(5-quinolinylamino)-
, methyl ester (CA INDEX NAME)




RN 720717-67-9 CAPLUS

CN 1(6H)-Pyridazineacetic acid, 4-acetyl-6-oxo-3-phenyl-5-(5-quinolinylamino)-
(CA INDEX NAME)




RN 720717-68-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-methyl-2-pyridinyl)amino]-6-
phenyl- (CA INDEX NAME)




RN 720717-69-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(1H-pyrazol-3-ylamino)-
(CA INDEX NAME)




RN 720717-70-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(1H-purin-6-ylamino)-
(9CI) (CA INDEX NAME)




RN 720717-71-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-methyl-5-isoxazolyl)amino]-6-
phenyl- (CA INDEX NAME)




RN 720717-72-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(8-hydroxy-5-quinolinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-73-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1H-indazol-7-ylamino)-6-phenyl- (CA INDEX NAME)



RN 720717-74-8 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-4-[(6-bromo-8-quinolinyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)



RN 720717-75-9 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(5-methyl-3-isoxazolyl)amino]-6-phenyl- (CA INDEX NAME)

phenyl- (CA INDEX NAME)




RN 720717-76-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(3-isoxazolylamino)-6-phenyl- (CA INDEX NAME)




RN 720717-77-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-phenyl-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-78-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-phenyl-4-(8-quinolinylamino)- (CA INDEX NAME)




RN 720717-79-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(1-methyl-1H-pyrazol-3-yl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-80-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(1-oxido-5-quinolinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-81-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-oxido-5-isoquinolinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720717-82-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-83-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-(8-quinolinylamino)- (CA INDEX NAME)




RN 720717-84-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-pyridinyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-85-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-pyridinyl)-4-(5-quinolinylamino)-
(CA INDEX NAME)




RN 720717-86-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(8-fluoro-5-quinolinyl)amino]-6-
phenyl- (CA INDEX NAME)




RN 720717-87-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-(8-
quinolinylamino)- (CA INDEX NAME)




RN 720717-88-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-89-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-(8-quinolinylamino)- (CA INDEX NAME)




RN 720717-90-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-91-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(1-oxido-5-quinolinyl)amino]- (CA INDEX NAME)



RN 720717-92-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methyl-5-quinolinyl)amino]-6-phenyl- (CA INDEX NAME)




IT 720717-93-1P, 5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(isoquinolin-5-yl)amino]pyridazin-3(2H)-one 720717-94-2P, 5-Acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(1-oxidoquinolin-5-yl)amino]pyridazin-3(2H)-one 720717-95-3P, 5-Acetyl-2-ethyl-6-(3-fluorophenyl)-4-[(quinolin-5-yl)amino]pyridazin-3(2H)-one 720717-96-4P, 5-Acetyl-2-ethyl-6-(3-fluorophenyl)-4-[(1-oxidoquinolin-5-yl)amino]pyridazin-3(2H)-one 720717-98-6P, 3-[[5-Acetyl-2-ethyl-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazin-4-yl]amino]benzamide 720717-99-7P, 5-Acetyl-2-ethyl-4-(isoquinolin-

1-ylamino)-6-phenylpyridazin-3(2H)-one 720718-00-3P,
 5-Acetyl-4-[(2-butylquinazolin-4-yl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-
 one 720718-01-4P, 5-Acetyl-4-(1,2-benzisothiazol-3-ylamino)-2-
 ethyl-6-phenylpyridazin-3(2H)-one 720718-02-5P,
 5-Acetyl-2-ethyl-6-phenyl-4-(pyridin-4-ylamino)pyridazin-3(2H)-one
 720718-03-6P, 5-Acetyl-2-ethyl-4-[(2-hydroxy-7H-purin-6-yl)amino]-
 6-phenylpyridazin-3(2H)-one 720718-04-7P, 5-Acetyl-2-ethyl-6-
 phenyl-4-(quinazolin-4-ylamino)pyridazin-3(2H)-one 720718-05-8P,
 5-Acetyl-4-[(4-chloro-1H-indazol-3-yl)amino]-2-ethyl-6-phenylpyridazin-
 3(2H)-one 720718-06-9P, 5-Acetyl-4-[(7-chloroquinolin-4-
 yl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 720718-07-0P,
 5-Acetyl-4-[(4,6-dichloropyrimidin-2-yl)amino]-2-ethyl-6-phenylpyridazin-
 3(2H)-one 720718-08-1P, 5-Acetyl-2-ethyl-4-[(6-hydroxy-2H-
 pyrazolo[3,4-d]pyrimidin-4-yl)amino]-6-phenylpyridazin-3(2H)-one
 720718-09-2P, 5-Acetyl-2-ethyl-4-[(2-methylquinolin-4-yl)amino]-6-
 phenylpyridazin-3(2H)-one 720718-10-5P, 5-Acetyl-2-ethyl-4-[(1H-
 imidazol-2-yl)amino]-6-phenylpyridazin-3(2H)-one 720718-11-6P,
 5-Acetyl-2-ethyl-6-phenyl-4-[(quinolin-4-yl)amino]pyridazin-3(2H)-one
 720718-12-7P, 5-Acetyl-4-(cinnolin-4-ylamino)-2-ethyl-6-
 phenylpyridazin-3(2H)-one 720718-13-8P, 5-Acetyl-2-ethyl-6-
 phenyl-4-[(1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]pyridazin-3(2H)-one
 720718-14-9P, 5-Acetyl-2-ethyl-6-phenyl-4-[(thieno[2,3-d]pyrimidin-
 4-yl)amino]pyridazin-3(2H)-one 720718-15-0P,
 5-Acetyl-2-ethyl-4-[(1H-indazol-6-yl)amino]-6-phenylpyridazin-3(2H)-one
 720718-16-1P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(2-
 methoxyphenyl)pyridazin-3(2H)-one 720718-17-2P,
 5-Acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(6-methoxyphenyl)-
 3-pyridazin-3(2H)-one 720718-18-3P, 5-Acetyl-2-ethyl-4-[(3-
 methoxyphenyl)amino]-6-(thien-3-yl)pyridazin-3(2H)-one
 720718-19-4P, 5-Acetyl-6-(benzo[b]furan-5-yl)-2-ethyl-4-[(3-
 fluorophenyl)amino]pyridazin-3(2H)-one 720718-20-7P,
 1-Ethyl-5-[(3-methoxyphenyl)amino]-N,N-dimethyl-6-oxo-3-(pyridin-3-yl)-1,6-
 dihydropyridazine-4-carboxamide 720718-21-8P,
 5-[(3-Chlorophenyl)amino]-1-ethyl-N-methyl-6-oxo-3-(pyridin-4-yl)-1,6-
 dihydropyridazine-4-carboxamide 720718-22-9P
 720718-23-0P, 2-Ethyl-4-[(3-fluorophenyl)amino]-5-(methoxyacetyl)-
 6-(pyridin-3-yl)pyridazin-3(2H)-one 720718-24-1P,
 5-[(Dimethylamino)acetyl]-2-ethyl-4-[(3-methoxyphenyl)amino]-6-(pyridin-3-
 yl)pyridazin-3(2H)-one 720718-25-2P, 2-Ethyl-4-[(3-
 fluorophenyl)amino]-5-[(methylamino)acetyl]-6-(pyridin-4-yl)pyridazin-
 3(2H)-one 720718-26-3P, 3-[[2-Ethyl-3-oxo-5-(3-phenylpropanoyl)-
 6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]amino]benzamide
 720718-29-6P, Methyl 5-[(5-acetyl-2-ethyl-3-oxo-6-phenyl-2,3-
 dihydropyridazin-4-yl)amino]quinoline-8-carboxylate 720718-30-9P
 , 5-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-
 yl)amino]quinoline-8-carboxylic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(PDE4 inhibitor; preparation of pyridazinones as PDE4 inhibitors)


RN 720717-93-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-(5-
 isoquinolinylamino)- (CA INDEX NAME)




RN 720717-94-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(1-oxido-5-quinolinyl)amino]- (CA INDEX NAME)




RN 720717-95-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-fluorophenyl)-4-(5-quinolinylamino)- (CA INDEX NAME)




RN 720717-96-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-fluorophenyl)-4-[(1-oxido-5-quinolinyl)amino]- (CA INDEX NAME)




RN 720717-98-6 CAPLUS

CN Benzamide, 3-[[5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-(3-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720717-99-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1-isoquinolinylamino)-6-phenyl- (CA INDEX NAME)




RN 720718-00-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-butyl-4-quinazolinyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720718-01-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-(1,2-benzisothiazol-3-ylamino)-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 720718-02-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(4-pyridinylamino)- (CA INDEX NAME)




RN 720718-03-6 CAPLUS

CN 2H-Purin-2-one, 6-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 720718-04-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(4-quinazolinylamino)-
(CA INDEX NAME)




RN 720718-05-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(4-chloro-1H-indazol-3-yl)amino]-2-ethyl-6-
phenyl- (CA INDEX NAME)




RN 720718-06-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(7-chloro-4-quinolinyl)amino]-2-ethyl-6-
phenyl- (CA INDEX NAME)




RN 720718-07-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(4,6-dichloro-2-pyrimidinyl)amino]-2-ethyl-
6-phenyl- (CA INDEX NAME)




RN 720718-08-1 CAPLUS

CN 6H-Pyrazolo[3,4-d]pyrimidin-6-one, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-1,2-dihydro- (CA INDEX NAME)




RN 720718-09-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methyl-4-quinolinyl)amino]-6-phenyl- (CA INDEX NAME)




RN 720718-10-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1H-imidazol-2-ylamino)-6-phenyl- (CA INDEX NAME)




RN 720718-11-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(4-quinolinylamino)- (CA INDEX NAME)




RN 720718-12-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-(4-cinnolinylamino)-2-ethyl-6-phenyl- (CA INDEX NAME)



RN 720718-13-8 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)- (CA INDEX NAME)




RN 720718-14-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-(thieno[2,3-d]pyrimidin-4-

ylamino)- (CA INDEX NAME)




RN 720718-15-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1H-indazol-6-ylamino)-6-phenyl-
(CA INDEX NAME)


RN 720718-16-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(2-methoxy-4-pyridinyl)- (CA INDEX NAME)




RN 720718-17-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-(2-methoxy-3-pyridinyl)- (CA INDEX NAME)




RN 720718-18-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-methoxyphenyl)amino]-6-(3-thienyl)- (CA INDEX NAME)




RN 720718-19-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(5-benzofuranyl)-2-ethyl-4-[(3-fluorophenyl)amino]- (CA INDEX NAME)




RN 720718-20-7 CAPLUS

CN 4-Pyridazinecarboxamide, 1-ethyl-1,6-dihydro-5-[(3-methoxyphenyl)amino]-N,N-dimethyl-6-oxo-3-(3-pyridinyl)- (CA INDEX NAME)




RN 720718-21-8 CAPLUS

CN 4-Pyridazinecarboxamide, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-N-methyl-6-oxo-3-(4-pyridinyl)- (CA INDEX NAME)




RN 720718-22-9 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(3-fluorophenyl)amino]-5-(hydroxyacetyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 720718-23-0 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(3-fluorophenyl)amino]-5-(methoxyacetyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 720718-24-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-[(dimethylamino)acetyl]-2-ethyl-4-[(3-methoxyphenyl)amino]-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 720718-25-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(3-fluorophenyl)amino]-5-[(methylamino)acetyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 720718-26-3 CAPLUS

CN Benzamide, 3-[[2-ethyl-2,3-dihydro-3-oxo-5-(1-oxo-3-phenylpropyl)-6-(4-pyridinyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 720718-29-6 CAPLUS

CN 8-Quinolinecarboxylic acid, 5-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, methyl ester (CA INDEX NAME)



RN 720718-30-9 CAPLUS

CN 8-Quinolinecarboxylic acid, 5-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




IT 720718-27-4P, Ethyl 4-acetyl-5-[(3-chlorophenyl)amino]-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyridazinones as PDE4 inhibitors)

RN 720718-27-4 CAPLUS

CN 3-Pyridazinecarboxylic acid, 4-acetyl-5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-, ethyl ester (CA INDEX NAME)



DOCUMENT NUMBER: 140:5060
 TITLE: Preparation of pyridazin-3(2H)-ones as
 Phosphodiesterase 4 (PDE4) inhibitors
 INVENTOR(S): Dal Piaz, Vittorio; Giovannoni, Maria Paola; Vergelli,
 Claudia; Aguilar, Izquierdo Nuria
 PATENT ASSIGNEE(S): Almirall Prodesfarma Sa, Spain; Aguilar Izquierdo,
 Nuria
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097613	A1	20031127	WO 2003-EP5056	20030514 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2195785	A1	20031201	ES 2002-1111	20020516 <--
ES 2195785	B1	20050316		
CA 2485896	A1	20031127	CA 2003-2485896	20030514 <--
AU 2003236648	A1	20031202	AU 2003-236648	20030514 <--
EP 1503992	A1	20050209	EP 2003-735387	20030514 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003010106	A	20050222	BR 2003-10106	20030514 <--
JP 2005533024	T	20051104	JP 2004-505346	20030514 <--
NZ 536604	A	20060728	NZ 2003-536604	20030514 <--
MX 2004PA11209	A	20050214	MX 2004-PA11209	20041111 <--
ZA 2004009173	A	20050729	ZA 2004-9173	20041111 <--
IN 2004DN03570	A	20050401	IN 2004-DN3570	20041116 <--
NO 2004005461	A	20050119	NO 2004-5461	20041215 <--
US 2006052379	A1	20060309	US 2005-513219	20050629 <--
PRIORITY APPLN. INFO.:			ES 2002-1111	A 20020516 <--
			WO 2003-EP5056	W 20030514 <--
OTHER SOURCE(S):	MARPAT 140:5060			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = H, acyl, alkoxycarbonyl, monoalkyl/dialkyl/carbamoyl, (un)substituted alkyl, (CH2)n-R6; n = 0 to 4; R6 = cycloalkyl, (un)substituted aryl, 3- to 7-membered heterocyclyl; R2 = R1, (un)substituted alkyl; R3, R5 = independently (un)substituted monocyclic or bicyclic aryl; R4 = H, OH and derivs., NH2 and derivs., (un)substituted alkyl, (CH2)n-R6; with the proviso that when R2 = H and R3, R4 = unsubstituted Ph, R1 is not methyl; and their pharmaceutical acceptable salts] were prepared as potent and selective inhibitors of Phosphodiesterase 4 (PDE4). Four

pharmaceutical compns. are given. For example, II was prepared by hydrogenation of 6-ethyl-3-methyl-4- phenylisoxazolo[3,4-d]pyridazin-7(6H)-one over Pd/C in ethanol, and reaction of the resulting 4-aminopyridazinone with 3-fluorophenylboronic acid in the presence of Cu(OAc)₂/TEA/mol. sieves/CH₂Cl₂. Selected I exhibited an IC₅₀ value < 20 nM for the inhibition of PDE4. I and their pharmaceutical compns. are useful for prevention and treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease (no data).

II 627493-25-8P, 5-Acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627493-30-5P, 5-Acetyl-4-[(3,5-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627493-36-1P, 5-Acetyl-4-[(3,5-dichlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627493-41-8P, 5-Acetyl-2-ethyl-4-[(3-nitrophenyl)amino]-6-phenylpyridazin-3(2H)-one 627493-45-2P, 5-Acetyl-2-ethyl-4-[(4-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627493-49-6P, 5-Acetyl-2-ethyl-4-[(2-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627493-53-2P, 5-Acetyl-2-ethyl-4-[(2-methoxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627493-57-6P, 5-Acetyl-2-ethyl-4-(1-naphthylamino)-6-phenylpyridazin-3(2H)-one 627493-61-2P, 5-Acetyl-2-ethyl-4-[[4-(methylthio)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627493-66-7P, 5-Acetyl-4-[(4-acetylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627493-70-3P, 5-Acetyl-4-[[4-(dimethylamino)phenyl]amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627493-74-7P, 5-Acetyl-2-ethyl-4-(2-naphthylamino)-6-phenylpyridazin-3(2H)-one 627493-78-1P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627493-82-7P, 5-Acetyl-2-ethyl-6-phenyl-4-[[3-(trifluoromethoxy)phenyl]amino]pyridazin-3(2H)-one 627493-86-1P, 5-Acetyl-2-ethyl-6-phenyl-4-[[2-(trifluoromethyl)phenyl]amino]pyridazin-3(2H)-one 627493-90-7P, 5-Acetyl-2-ethyl-4-[(2,5-dimethoxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627493-94-1P, 5-Acetyl-2-ethyl-4-[(2-fluoro-3-methoxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627493-98-5P, 5-Acetyl-4-[(2,3-dichlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627494-02-4P, 5-Acetyl-4-[(5-chloro-2-methoxyphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627494-06-8P, 5-Acetyl-2-ethyl-4-[(5-fluoro-2-methoxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627494-10-4P, Methyl 4-[[5-acetyl-2-ethyl-6-[4-(methylthio)phenyl]-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzoate 627494-14-8P, 5-Acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-[4-(methylthio)phenyl]-pyridazin-3(2H)-one 627494-18-2P, 4-[[5-Acetyl-2-ethyl-6-[4-(methylthio)phenyl]-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzoic acid 627494-22-8P, 5-Acetyl-2-ethyl-6-[4-(methylthio)phenyl]-4-(1-naphthylamino)pyridazin-3(2H)-one 627494-26-2P, 5-Butyryl-2-ethyl-4-[(3-fluorophenyl)amino]-6-[4-(methylthio)phenyl]pyridazin-3(2H)-one 627494-30-8P, 2-Ethyl-5-(2-ethylbutanoyl)-4-[(3-fluorophenyl)amino]-6-[4-(methylthio)phenyl]pyridazin-3(2H)-one 627494-34-2P, 2-Ethyl-5-(2-ethylbutanoyl)-6-[4-(methylthio)phenyl]-4-[(naphth-1-yl)amino]pyridazin-3(2H)-one 627494-38-6P, Methyl 4-[[5-acetyl-2-ethyl-6-[4-(methylsulfinyl)phenyl]-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzoate 627494-42-2P, 5-Acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-[4-(methylsulfinyl)phenyl]pyridazin-3(2H)-one 627494-46-6P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-[4-(methylsulfinyl)phenyl]pyridazin-3(2H)-one 627494-50-2P, 5-Acetyl-2-ethyl-4-[(2-methylphenyl)amino]-6-[4-(methylsulfinyl)phenyl]pyridazin-3(2H)-one 627494-54-6P, 5-Acetyl-2-ethyl-6-[4-(methylsulfinyl)phenyl]-4-[(1-naphthyl)amino]pyridazin-3(2H)-one 627494-58-0P,

5-Acetyl-2-ethyl-6-[4-(methylsulfinyl)phenyl]-4-[(3-nitrophenyl)amino]pyridazin-3(2H)-one 627494-62-6P,
5-Acetyl-2-ethyl-6-[4-(methylsulfinyl)phenyl]-4-[(2-methoxyphenyl)amino]pyridazin-3(2H)-one 627494-66-6P,
5-Acetyl-2-ethyl-6-[4-(methylsulfinyl)phenyl]-4-[(3-methoxyphenyl)amino]pyridazin-3(2H)-one 627494-70-6P,
5-Acetyl-6-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-ethyl-4-[(3-fluorophenyl)amino]pyridazin-3(2H)-one 627494-74-0P,
5-Acetyl-6-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-ethyl-4-[(1-naphthyl)amino]pyridazin-3(2H)-one 627494-78-4P,
5-Acetyl-2-methyl-4-[(1-naphthyl)amino]-6-phenylpyridazin-3(2H)-one 627494-82-0P, 5-Acetyl-4-[(3,5-difluorophenyl)amino]-2-methyl-6-phenylpyridazin-3(2H)-one 627494-85-3P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-methyl-6-phenylpyridazin-3(2H)-one 627494-88-6P, 5-Acetyl-2-benzyl-4-[(3,5-difluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627494-91-1P, 5-Acetyl-2-benzyl-4-[(3-fluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627494-94-4P, 5-Acetyl-2-benzyl-4-[(3-chlorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627494-97-7P, 5-Acetyl-2-(cyclopropylmethyl)-4-(1-naphthylamino)-6-phenylpyridazin-3(2H)-one 627495-00-5P, 5-Acetyl-2-(cyclopropylmethyl)-4-[(3-fluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627495-03-8P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-phenylpyridazin-3(2H)-one 627495-06-1P, 5-Acetyl-4-[(1-naphthyl)amino]-6-phenyl-2-[(pyridin-4-yl)methyl]pyridazin-3(2H)-one 627495-09-4P, 5-Acetyl-4-[(3-fluorophenyl)amino]-6-phenyl-2-[(pyridin-4-yl)methyl]pyridazin-3(2H)-one 627495-12-9P, 5-Acetyl-2-ethyl-4-[(3-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627495-15-2P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid 627495-19-6P, 2-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid 627495-22-1P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-25-4P, 5-Acetyl-4-[(3-bromophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-28-7P, 5-Acetyl-4-[(3,4-dimethoxyphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-31-2P, 5-Acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627495-34-5P, 5-Acetyl-4-[(1,1'-biphenyl-4-yl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-37-8P, 5-Acetyl-2-ethyl-6-phenyl-4-[(5,6,7,8-tetrahydronaphthalen-1-yl)amino]pyridazin-3(2H)-one 627495-40-3P, 5-Acetyl-4-[[3-(cyclopentyloxy)-4-methoxyphenyl]amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-43-6P, 5-Acetyl-2-ethyl-4-(N-methyl-N-phenylamino)-6-phenylpyridazin-3(2H)-one 627495-46-9P, 5-Acetyl-4-[(1,3-benzodioxol-5-yl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-49-2P, 5-Acetyl-2-ethyl-4-[(4-methoxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627495-52-7P, 5-Acetyl-4-[(4-chlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-56-1P, 5-Acetyl-4-[(4-bromophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-60-7P, 5-Acetyl-2-ethyl-6-phenyl-4-[[3-(trifluoromethyl)phenyl]amino]pyridazin-3(2H)-one 627495-65-2P, 5-Acetyl-4-[(3-chloro-4-methoxyphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627495-70-9P, 5-Acetyl-2-ethyl-4-[(3-hydroxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627495-75-4P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid 627495-80-1P, 5-Acetyl-2-ethyl-4-[(2-fluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627495-85-6P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid 627495-90-3P, 5-Acetyl-2-ethyl-4-[(4-fluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627495-95-8P, 2-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-

dihydropyridazin-4-yl)amino]-4-fluorobenzoic acid 627495-99-2P,
3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzonitrile 627496-03-1P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-2-hydroxybenzoic acid 627496-06-4P, 5-Acetyl-2-ethyl-4-[(3-hydroxy-4-methoxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627496-10-0P,
4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzamide 627496-14-4P, 5-Acetyl-2-ethyl-4-[(3-(methylthio)phenyl)amino]-6-phenylpyridazin-3(2H)-one 627496-17-7P,
5-Acetyl-2-ethyl-4-[(3-methoxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627496-20-2P, 5-Acetyl-4-[(3-acetylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627496-23-5P, [4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]phenyl]acetic acid 627496-26-8P, 5-Acetyl-4-[4-(tert-butyl)phenylamino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627496-29-1P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzenesulfonamide 627496-32-6P, 4-[4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]phenyl]-4-oxobutanoic acid 627496-35-9P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-N-butylbenzenesulfonamide 627496-38-2P, 5-Acetyl-2-ethyl-4-[(1-oxo-2,3-dihydro-1H-inden-5-yl)amino]-6-phenylpyridazin-3(2H)-one 627496-41-7P,
N-[4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]phenyl]acetamide 627496-43-9P, 4-[[5-Acetyl-6-(3-chlorophenyl)-2-ethyl-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzoic acid 627496-46-2P, 5-Acetyl-6-(3-chlorophenyl)-4-[(3-chlorophenyl)amino]-2-ethylpyridazin-3(2H)-one 627496-48-4P,
5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(3-fluorophenyl)amino]pyridazin-3(2H)-one 627496-50-8P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(4-fluorophenyl)pyridazin-3(2H)-one 627496-52-0P,
5-Acetyl-4-[(3-bromophenyl)amino]-2-ethyl-6-(3-fluorophenyl)pyridazin-3(2H)-one 627496-54-2P, 5-Acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-(3-fluorophenyl)pyridazin-3(2H)-one 627496-57-5P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(3-fluorophenyl)pyridazin-3(2H)-one 627496-59-7P,
5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(3-nitrophenyl)pyridazin-3(2H)-one 627496-62-2P, 5-Acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-(3-nitrophenyl)pyridazin-3(2H)-one 627496-65-5P, 4-[[5-Acetyl-2-ethyl-6-(3-nitrophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzoic acid 627496-68-8P,
5-Acetyl-4-[(3-bromophenyl)amino]-2-ethyl-6-(3-nitrophenyl)pyridazin-3(2H)-one 627496-71-3P, 5-Acetyl-2-ethyl-4-(naphthalen-1-ylamino)-6-(3-nitrophenyl)pyridazin-3(2H)-one 627496-74-6P,
5-Butyryl-4-[(3-chlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627496-77-9P, 5-Acetyl-4-[(3-chlorophenyl)amino]-6-phenyl-2-n-propylpyridazin-3(2H)-one 627496-80-4P, 5-Acetyl-2-butyl-4-[(3-chlorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627496-82-6P,
5-Acetyl-4-[(3-bromophenyl)amino]-2-butyl-6-phenylpyridazin-3(2H)-one 627496-84-8P, 5-Acetyl-4-[N-(3,5-dichlorophenyl)-N-(3-fluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627496-86-0P, 5-Acetyl-4-[bis(3-fluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627496-89-3P, 5-Acetyl-4-[bis(3-chlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627496-92-8P, 5-Acetyl-2-ethyl-4-[bis(3-methylsulfonylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627496-95-1P, 5-Acetyl-4-[bis(3-acetylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627496-98-4P, 5-Acetyl-4-[bis(3,5-dichlorophenyl)amino]-2-ethyl-6-phenyl-2H-pyridazin-3-one 627497-01-2P, Methyl 4-[N-[5-acetyl-2-ethyl-6-(4-methylsulfinylphenyl)-3-oxo-2,3-dihydropyridazin-4-yl]-N-[4-

(methoxycarbonyl)phenyl]amino]benzoate 627497-04-5P,
5-Acetyl-2-cyclopropylmethyl-4-(3,5-difluorophenylamino)-6-phenyl-2H-pyridazin-3-one 627497-08-9P, 5-Acetyl-4-(3-fluorophenylamino)-2-methyl-6-phenyl-2H-pyridazin-3-one 627497-12-5P,
4-(5-Acetyl-2-methyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-ylamino)benzoic acid 627497-16-9P, 5-Acetyl-4-(3,5-dichlorophenylamino)-2,6-diphenyl-2H-pyridazin-3-one 627497-22-7P, 5-Acetyl-4-(3-fluorophenylamino)-2,6-diphenyl-2H-pyridazin-3-one 627497-26-1P,
5-Acetyl-4-[(naphthalen-1-yl)amino]-2,6-diphenyl-2H-pyridazin-3-one 627497-31-8P, 5-Acetyl-4-(3,5-difluorophenylamino)-2,6-diphenyl-2H-pyridazin-3-one 627497-34-1P, 5-Acetyl-4-(3-chlorophenylamino)-2,6-diphenyl-2H-pyridazin-3-one 627497-37-4P,
4-(3-Chlorophenylamino)-2-ethyl-6-phenyl-5-(1-phenylmethanoyl)pyridazin-3(2H)-one 627497-40-9P, 5-[(3-Chlorophenyl)amino]-1-ethyl-6-oxo-3-phenyl-1,6-dihydropyridazine-4-carboxaldehyde 627497-43-2P,
Methyl 5-[(3-chlorophenyl)amino]-1-ethyl-6-oxo-3-phenyl-1,6-dihydropyridazine-4-carboxylate 627497-46-5P,
4-[(3-Chlorophenyl)amino]-2-ethyl-6-phenyl-5-(3-phenylpropanoyl)pyridazin-3(2H)-one 627497-49-8P, 4-[(3,5-Dichlorophenyl)amino]-2-ethyl-6-phenyl-5-(3-phenylpropanoyl)pyridazin-3(2H)-one 627497-52-3P,
3-[[2-Ethyl-3-oxo-6-phenyl-5-(3-phenylpropanoyl)-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627497-55-6P, 4-[[2-Ethyl-3-oxo-6-phenyl-5-(3-phenylpropanoyl)-2,3-dihydropyridazin-4-yl]amino]benzoic acid 627497-58-9P,
4-[(3-Chlorophenyl)amino]-2-ethyl-6-phenyl-5-[3-(thien-3-yl)propanoyl]pyridazin-3(2H)-one 627497-61-4P,
4-[(3-Chlorophenyl)amino]-2-ethyl-6-phenyl-5-[3-(pyridin-3-yl)propanoyl]pyridazin-3(2H)-one 627497-64-7P,
5-Acetyl-2-benzyl-4-(1-naphthylamino)-6-phenylpyridazin-3(2H)-one 627497-67-0P, 4-[(5-Acetyl-2-benzyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid 627497-70-5P,
5-Acetyl-4-[(3,5-difluorophenyl)amino]-6-phenyl-2-(pyridin-4-ylmethyl)-pyridazin-3(2H)-one 627497-73-8P, 5-Acetyl-4-[(3-chlorophenyl)amino]-6-phenyl-2-(pyridin-4-ylmethyl)-pyridazin-3(2H)-one 627497-76-1P,
4-[(5-Acetyl-3-oxo-2,6-diphenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid 627497-79-4P, 5-Acetyl-2-(cyclopropylmethyl)-4-[(2-fluorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627497-82-9P,
5-Acetyl-4-[(2-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-phenylpyridazin-3(2H)-one 627497-85-2P,
5-Acetyl-2-(cyclopropylmethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627497-88-5P, 3-[[5-Acetyl-2-(cyclopropylmethyl)-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627497-91-0P,
4-[[5-Acetyl-2-(cyclopropylmethyl)-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl]amino]benzoic acid 627497-94-3P, 5-Acetyl-2-isopropyl-4-(1-naphthylamino)-6-phenylpyridazin-3(2H)-one 627497-97-6P, 5-Acetyl-4-[(3,5-difluorophenyl)amino]-2-isopropyl-6-phenylpyridazin-3(2H)-one 627498-00-4P,
5-Acetyl-4-[(3-fluorophenyl)amino]-2-isopropyl-6-phenylpyridazin-3(2H)-one 627498-03-7P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-isopropyl-6-phenylpyridazin-3(2H)-one 627498-06-0P,
5-Acetyl-4-[(3,5-dichlorophenyl)amino]-2-isopropyl-6-phenylpyridazin-3(2H)-one 627498-09-3P, 4-[(5-Acetyl-2-isopropyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoic acid 627498-12-8P,
5-Acetyl-4-[(2-fluorophenyl)amino]-2-isopropyl-6-phenylpyridazin-3(2H)-one 627498-15-1P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-isopropyl-6-phenylpyridazin-3(2H)-one 627498-18-4P,
3-[(5-Acetyl-2-isopropyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzonitrile 627498-21-9P,
5-Acetyl-4-[[4-(hydroxymethyl)phenyl]amino]-2-isopropyl-6-phenylpyridazin-3(2H)-one 627498-24-2P, 5-Acetyl-4-[(2-fluorophenyl)amino]-2-(2-hydroxyethyl)-6-phenylpyridazin-3(2H)-one 627498-27-5P,

5-Acetyl-4-[(2-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-phenylpyridazin-3(2H)-one 627498-30-0P, 3-[[5-Acetyl-2-(2-hydroxyethyl)-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627498-33-3P, 5-Acetyl-2-(2-hydroxyethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627498-36-6P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-phenylpyridazin-3(2H)-one 627498-39-9P, 5-Acetyl-6-(3-fluorophenyl)-4-[(2-fluorophenyl)amino]-2-(2-hydroxyethyl)pyridazin-3(2H)-one 627498-42-4P, 5-Acetyl-4-[(2-chlorophenyl)amino]-6-(3-fluorophenyl)-2-(2-hydroxyethyl)pyridazin-3(2H)-one 627498-45-7P, 3-[[5-Acetyl-6-(3-fluorophenyl)-2-(2-hydroxyethyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627498-48-0P, 5-Acetyl-6-(3-fluorophenyl)-2-(2-hydroxyethyl)-4-[[4-(hydroxymethyl)phenyl]amino]pyridazin-3(2H)-one 627498-51-5P, 5-Acetyl-4-[(3-chlorophenyl)amino]-6-(3-fluorophenyl)-2-(2-hydroxyethyl)pyridazin-3(2H)-one 627498-54-8P, 3-[[5-Acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzamide 627498-57-1P, 5-Acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-4-[[4-(hydroxymethyl)phenyl]amino]pyridazin-3(2H)-one 627498-60-6P, 3-[[5-Acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627498-64-0P, 5-Acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-4-[(2-fluorophenyl)amino]pyridazin-3(2H)-one 627498-68-4P, 5-Acetyl-6-(3-chlorophenyl)-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)pyridazin-3(2H)-one 627498-71-9P, 3-[[5-Acetyl-2-(cyclopropylmethyl)-6-(3-fluorophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzamide 627498-74-2P, 5-Acetyl-2-(cyclopropylmethyl)-6-(3-fluorophenyl)-4-[[4-(hydroxymethyl)phenyl]amino]pyridazin-3(2H)-one 627498-76-4P, 3-[[5-Acetyl-6-(3-fluorophenyl)-2-isopropyl-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzamide 627498-79-7P, 5-Acetyl-6-(3-fluorophenyl)-4-[[4-(hydroxymethyl)phenyl]amino]-2-isopropylpyridazin-3(2H)-one 627498-82-2P, 3-[[5-Acetyl-6-(3-fluorophenyl)-2-isopropyl-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627498-84-4P, 5-Acetyl-6-(3-fluorophenyl)-4-[(2-fluorophenyl)amino]-2-isopropylpyridazin-3(2H)-one 627498-86-6P, 5-Acetyl-4-[(3-chlorophenyl)amino]-6-(3-fluorophenyl)-2-isopropylpyridazin-3(2H)-one 627498-88-8P, 5-Acetyl-4-[(2-chlorophenyl)amino]-6-(3-fluorophenyl)-2-isopropylpyridazin-3(2H)-one 627498-90-2P, 3-[[5-Acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627498-92-4P, 3-[[5-Acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzamide 627498-94-6P, 3-[[5-Acetyl-6-(3-chlorophenyl)-2-ethyl-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzamide 627498-96-8P, 5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]pyridazin-3(2H)-one 627498-98-0P, 3-[[5-Acetyl-6-(3-chlorophenyl)-2-ethyl-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627499-00-7P, 5-Acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(2-fluorophenyl)amino]pyridazin-3(2H)-one 627499-02-9P, 5-Acetyl-6-(3-chlorophenyl)-4-[(2-chlorophenyl)amino]-2-ethylpyridazin-3(2H)-one 627499-04-1P, 5-Acetyl-2-ethyl-6-(3-fluorophenyl)-4-[[4-(hydroxymethyl)phenyl]amino]pyridazin-3(2H)-one 627499-06-3P, 3-[[5-Acetyl-2-ethyl-6-(3-fluorophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzamide 627499-08-5P, 3-[[5-Acetyl-2-ethyl-6-(3-fluorophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627499-10-9P, 5-Acetyl-2-ethyl-6-(3-fluorophenyl)-4-[(2-fluorophenyl)amino]pyridazin-3(2H)-one 627499-12-1P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-(3-fluorophenyl)pyridazin-3(2H)-one 627499-14-3P, 5-Acetyl-2-ethyl-6-(4-fluorophenyl)-4-

[[4-(hydroxymethyl)phenyl]amino]pyridazin-3(2H)-one 627499-16-5P,
4-[[5-Acetyl-2-ethyl-6-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627499-18-7P, 3-[[5-Acetyl-2-ethyl-6-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzamide 627499-20-1P, 3-[[5-Acetyl-2-ethyl-6-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazin-4-yl]amino]benzonitrile 627499-22-3P, 5-Acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(2-fluorophenyl)amino]pyridazin-3(2H)-one 627499-24-5P, 5-Acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-(4-fluorophenyl)pyridazin-3(2H)-one 627499-26-7P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(1-naphthyl)pyridazin-3(2H)-one 627499-28-9P, 5-Acetyl-4-[(2,4-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-30-3P, 5-Acetyl-4-[(3,4-dichlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-32-5P, 5-Acetyl-4-[(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-34-7P, 5-Acetyl-4-[(2-chloro-6-methylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-36-9P, 5-Acetyl-2-ethyl-4-[(5-fluoro-2-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-38-1P, 5-Acetyl-2-ethyl-4-[(2-methyl-5-nitrophenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-40-5P, 5-Acetyl-4-[(2,3-dimethylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-42-7P, 5-Acetyl-4-[(2,6-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-44-9P, 5-Acetyl-4-[(2,5-dimethylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-46-1P, 5-Acetyl-4-[(2,5-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-48-3P, 5-Acetyl-2-ethyl-4-[(2-fluoro-5-nitrophenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-50-7P, 5-Acetyl-2-ethyl-4-[(3-fluoro-4-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-52-9P, 5-Acetyl-4-[(3,4-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-54-1P, 5-Acetyl-4-[(2-bromophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-56-3P, 5-Acetyl-4-[(2,3-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-58-5P, 5-Acetyl-4-[(5-chloro-2-methylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-60-9P, 5-Acetyl-4-[(2-chloro-5-methylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-62-1P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-3-methylbenzoic acid 627499-64-3P, 5-Acetyl-4-[(2,4-dichlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-66-5P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-2-chlorobenzoic acid 627499-68-7P, 5-Acetyl-4-[(2-chloro-5-nitrophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-70-1P, 5-Acetyl-2-ethyl-4-[(7-hydroxy-1-naphthyl)amino]-6-phenylpyridazin-3(2H)-one 627499-72-3P, 5-Acetyl-2-ethyl-4-[(2-hydroxy-4-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-74-5P, 5-Acetyl-2-ethyl-4-[(2-hydroxy-4-nitrophenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-76-7P, 5-Acetyl-2-ethyl-4-[(2-hydroxy-5-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-78-9P, 5-Acetyl-2-ethyl-4-[(2-hydroxy-5-nitrophenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-80-3P, 5-Acetyl-2-ethyl-4-[(2-methoxy-4-nitrophenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-82-5P, 5-Acetyl-2-ethyl-6-phenyl-4-[[4-(trifluoromethoxy)phenyl]amino]pyridazin-3(2H)-one 627499-85-8P, 5-Acetyl-4-[(3-ethoxyphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627499-87-0P, 5-Acetyl-2-ethyl-4-[(2-methoxy-5-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-89-2P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-1-naphthonitrile 627499-91-6P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-5-nitrobenzoic acid 627499-93-8P, 5-Acetyl-2-ethyl-4-[(3-mercaptophenyl)amino]-6-phenylpyridazin-3(2H)-one 627499-95-0P, 5-Acetyl-4-[(2-chloro-5-methoxyphenyl)amino]-2-ethyl-


6-phenylpyridazin-3(2H)-one 627499-97-2P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-3-methoxybenzoic acid 627499-99-4P, 5-Acetyl-2-ethyl-4-[[3-(1-hydroxyethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627500-01-0P, 5-Acetyl-2-ethyl-4-[[3-(hydroxymethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627500-03-2P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-3-hydroxybenzoic acid 627500-05-4P, 5-Acetyl-2-ethyl-4-[[4-(1-hydroxyethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627500-07-6P, 5-Acetyl-4-[(3,5-dimethoxyphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-09-8P, 5-Acetyl-4-[(2,6-dimethylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-11-2P, 5-Acetyl-2-ethyl-4-[[4-(2-hydroxyethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627500-13-4P, 5-Acetyl-2-ethyl-4-[(4-nitrophenyl)amino]-6-phenylpyridazin-3(2H)-one 627500-15-6P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzonitrile 627500-17-8P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzamide 627500-19-0P, 5-Acetyl-2-ethyl-4-[[2-(hydroxymethyl)phenyl]amino]-6-phenylpyridazin-3(2H)-one 627500-21-4P, 2-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4 inhibitor; preparation of pyridazinones as PDE4 inhibitors)


RN 627493-25-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627493-30-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-difluorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627493-36-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-dichlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627493-41-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-nitrophenyl)amino]-6-phenyl-
(CA INDEX NAME)




RN 627493-45-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-methylphenyl)amino]-6-phenyl-
(CA INDEX NAME)




RN 627493-49-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methylphenyl)amino]-6-phenyl-
(CA INDEX NAME)




RN 627493-53-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methoxyphenyl)amino]-6-phenyl-
(CA INDEX NAME)




RN 627493-57-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1-naphthalenylamino)-6-phenyl-
(CA INDEX NAME)




RN 627493-61-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[4-(methylthio)phenyl]amino]-6-phenyl-
(CA INDEX NAME)




RN 627493-66-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(4-acetylphenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)




RN 627493-70-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[[4-(dimethylamino)phenyl]amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627493-74-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(2-naphthalenylamino)-6-phenyl- (CA INDEX NAME)




RN 627493-78-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627493-82-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-[[3-(trifluoromethoxy)phenyl]amino]- (CA INDEX NAME)




RN 627493-86-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-[[2-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)




RN 627493-90-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,5-dimethoxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627493-94-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-fluoro-3-methoxyphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627493-98-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,3-dichlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627494-02-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(5-chloro-2-methoxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627494-06-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(5-fluoro-2-methoxyphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627494-10-4 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2-ethyl-2,3-dihydro-6-[4-(methylthio)phenyl]-3-oxo-4-pyridazinyl]amino]-, methyl ester (CA INDEX NAME)




RN 627494-14-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-[4-(methylthio)phenyl]- (CA INDEX NAME)




RN 627494-18-2 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2-ethyl-2,3-dihydro-6-[4-(methylthio)phenyl]-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627494-22-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-[4-(methylthio)phenyl]-4-(1-naphthalenylamino)- (CA INDEX NAME)




RN 627494-26-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-4-[(3-fluorophenyl)amino]-6-[4-(methylthio)phenyl]-5-(1-oxobutyl)- (CA INDEX NAME)




RN 627494-30-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-(2-ethyl-1-oxobutyl)-4-[(3-fluorophenyl)amino]-6-[4-(methylthio)phenyl]- (CA INDEX NAME)




RN 627494-34-2 CAPLUS

CN 3(2H)-Pyridazinone, 2-ethyl-5-(2-ethyl-1-oxobutyl)-6-[4-(methylthio)phenyl]-4-(1-naphthalenylamino)- (CA INDEX NAME)




RN 627494-38-6 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2-ethyl-2,3-dihydro-6-[4-(methylsulfinyl)phenyl]-3-oxo-4-pyridazinyl]amino]-, methyl ester (CA INDEX NAME)




RN 627494-42-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-[4-(methylsulfinyl)phenyl]- (CA INDEX NAME)




RN 627494-46-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-[4-(methylsulfinyl)phenyl]- (CA INDEX NAME)




RN 627494-50-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methylphenyl)amino]-6-[4-(methylsulfinyl)phenyl]- (CA INDEX NAME)




RN 627494-54-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-[4-(methylsulfinyl)phenyl]-4-(1-naphthalenylamino)- (CA INDEX NAME)




RN 627494-58-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-[4-(methylsulfinyl)phenyl]-4-[(3-nitrophenyl)amino]- (CA INDEX NAME)




RN 627494-62-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methoxyphenyl)amino]-6-[4-(methylsulfinyl)phenyl]- (CA INDEX NAME)




RN 627494-66-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-methoxyphenyl)amino]-6-[4-(methylsulfinyl)phenyl]- (CA INDEX NAME)




RN 627494-70-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-ethyl-4-[(3-fluorophenyl)amino]- (CA INDEX NAME)




RN 627494-74-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-ethyl-4-(1-naphthalenylamino)- (CA INDEX NAME)




RN 627494-78-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-methyl-4-(1-naphthalenylamino)-6-phenyl- (CA INDEX NAME)




RN 627494-82-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-difluorophenyl)amino]-2-methyl-6-phenyl- (CA INDEX NAME)




RN 627494-85-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-methyl-6-phenyl- (CA INDEX NAME)




RN 627494-88-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-difluorophenyl)amino]-6-phenyl-2-(phenylmethyl)- (CA INDEX NAME)




RN 627494-91-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-fluorophenyl)amino]-6-phenyl-2-(phenylmethyl)- (CA INDEX NAME)




RN 627494-94-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-6-phenyl-2-(phenylmethyl)- (CA INDEX NAME)




RN 627494-97-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-(1-naphthalenylamino)-6-phenyl- (CA INDEX NAME)




RN 627495-00-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[(3-fluorophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627495-03-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-phenyl- (CA INDEX NAME)




RN 627495-06-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-(1-naphthalenylamino)-6-phenyl-2-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 627495-09-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-fluorophenyl)amino]-6-phenyl-2-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 627495-12-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-methylphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627495-15-2 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627495-19-6 CAPLUS

CN Benzoic acid, 2-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627495-22-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627495-25-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-bromophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627495-28-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,4-dimethoxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627495-31-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 627495-34-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-([1,1'-biphenyl]-4-ylamino)-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627495-37-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-[(5,6,7,8-tetrahydro-1-naphthalenyl)amino]- (CA INDEX NAME)




RN 627495-40-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[[3-(cyclopentyloxy)-4-methoxyphenyl]amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627495-43-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(methoxyphenylamino)-6-phenyl- (CA INDEX NAME)




RN 627495-46-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-(1,3-benzodioxol-5-ylamino)-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627495-49-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-methoxyphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627495-52-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(4-chlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627495-56-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(4-bromophenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)




RN 627495-60-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-[[3-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)




RN 627495-65-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chloro-4-methoxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627495-70-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-hydroxyphenyl)amino]-6-phenyl-
(CA INDEX NAME)




RN 627495-75-4 CAPLUS

CN Benzoic acid, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627495-80-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-fluorophenyl)amino]-6-phenyl-
(CA INDEX NAME)




RN 627495-85-6 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 627495-90-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-fluorophenyl)amino]-6-phenyl-
(CA INDEX NAME)


RN 627495-95-8 CAPLUS

CN Benzoic acid, 2-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-4-fluoro- (CA INDEX NAME)




RN 627495-99-2 CAPLUS

CN Benzonitrile, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627496-03-1 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-2-hydroxy- (CA INDEX NAME)




RN 627496-06-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-hydroxy-4-methoxyphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627496-10-0 CAPLUS

CN Benzamide, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627496-14-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[3-(methylthio)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 627496-17-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-methoxyphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627496-20-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-acetylphenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)




RN 627496-23-5 CAPLUS

CN Benzeneacetic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627496-26-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[[4-(1,1-dimethylethyl)phenyl]amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627496-29-1 CAPLUS

CN Benzenesulfonamide, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627496-32-6 CAPLUS

CN Benzenebutanoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-γ-oxo- (CA INDEX NAME)




RN 627496-35-9 CAPLUS

CN Benzenesulfonamide, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-N-butyl- (CA INDEX NAME)




RN 627496-38-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627496-41-7 CAPLUS

CN Acetamide, N-[4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]phenyl]- (CA INDEX NAME)




RN 627496-43-9 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-6-(3-chlorophenyl)-2-ethyl-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627496-46-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-4-[(3-chlorophenyl)amino]-2-ethyl- (CA INDEX NAME)




RN 627496-48-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(3-fluorophenyl)amino]- (CA INDEX NAME)




RN 627496-50-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 627496-52-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-bromophenyl)amino]-2-ethyl-6-(3-fluorophenyl)- (CA INDEX NAME)




RN 627496-54-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-fluorophenyl)-4-[(3-fluorophenyl)amino]- (CA INDEX NAME)




RN 627496-57-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(3-fluorophenyl)- (CA INDEX NAME)




RN 627496-59-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(3-nitrophenyl)- (CA INDEX NAME)




RN 627496-62-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluorophenyl)amino]-6-(3-nitrophenyl)- (CA INDEX NAME)




RN 627496-65-5 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2-ethyl-2,3-dihydro-6-(3-nitrophenyl)-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627496-68-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-bromophenyl)amino]-2-ethyl-6-(3-nitrophenyl)- (CA INDEX NAME)




RN 627496-71-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-(1-naphthalenylamino)-6-(3-nitrophenyl)- (CA INDEX NAME)




RN 627496-74-6 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-oxobutyl)-6-phenyl- (CA INDEX NAME)




RN 627496-77-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-6-phenyl-2-propyl- (CA INDEX NAME)




RN 627496-80-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-butyl-4-[(3-chlorophenyl)amino]-6-phenyl-
(CA INDEX NAME)




RN 627496-82-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-bromophenyl)amino]-2-butyl-6-phenyl-
(CA INDEX NAME)




RN 627496-84-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-dichlorophenyl)(3-fluorophenyl)amino]-
2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627496-86-0 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-fluorophenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)




RN 627496-89-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-chlorophenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)

RN 627496-92-8 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis[3-(methylthio)phenyl]amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)

RN 627496-95-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3-acetylphenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)


RN 627496-98-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[bis(3,5-dichlorophenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)




RN 627497-01-2 CAPLUS

CN Benzoic acid, 4,4'-[[5-acetyl-2-ethyl-2,3-dihydro-6-[4-(methylsulfinyl)phenyl]-3-oxo-4-pyridazinyl]imino]bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 627497-04-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[(3,5-difluorophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627497-08-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-fluorophenyl)amino]-2-methyl-6-phenyl- (CA INDEX NAME)




RN 627497-12-5 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2,3-dihydro-2-methyl-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627497-16-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-dichlorophenyl)amino]-2,6-diphenyl- (CA INDEX NAME)




RN 627497-22-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-fluorophenyl)amino]-2,6-diphenyl- (CA INDEX NAME)




RN 627497-26-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-(1-naphthalenylamino)-2,6-diphenyl- (CA INDEX NAME)




RN 627497-31-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-difluorophenyl)amino]-2,6-diphenyl-
(CA INDEX NAME)




RN 627497-34-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2,6-diphenyl- (CA
INDEX NAME)




RN 627497-37-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-benzoyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-phenyl-
(CA INDEX NAME)




RN 627497-40-9 CAPLUS

CN 4-Pyridazinecarboxaldehyde, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl- (CA INDEX NAME)




RN 627497-43-2 CAPLUS

CN 4-Pyridazinecarboxylic acid, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl-, methyl ester (CA INDEX NAME)




RN 627497-46-5 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-oxo-3-phenylpropyl)-6-phenyl- (CA INDEX NAME)




RN 627497-49-8 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3,5-dichlorophenyl)amino]-2-ethyl-5-(1-oxo-3-phenylpropyl)-6-phenyl- (CA INDEX NAME)




RN 627497-52-3 CAPLUS

CN Benzonitrile, 3-[[2-ethyl-2,3-dihydro-3-oxo-5-(1-oxo-3-phenylpropyl)-6-phenyl-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627497-55-6 CAPLUS

CN Benzoic acid, 4-[[2-ethyl-2,3-dihydro-3-oxo-5-(1-oxo-3-phenylpropyl)-6-phenyl-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627497-58-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-5-[1-oxo-3-(3-thienyl)propyl]-6-phenyl- (CA INDEX NAME)




RN 627497-61-4 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-2-ethyl-5-[1-oxo-3-(3-pyridinyl)propyl]-6-phenyl- (CA INDEX NAME)




RN 627497-64-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-(1-naphthalenylamino)-6-phenyl-2-(phenylmethyl)- (CA INDEX NAME)




RN 627497-67-0 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2,3-dihydro-3-oxo-6-phenyl-2-(phenylmethyl)-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627497-70-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-difluorophenyl)amino]-6-phenyl-2-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 627497-73-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-6-phenyl-2-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 627497-76-1 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2,3-dihydro-3-oxo-2,6-diphenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627497-79-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[(2-fluorophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627497-82-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-(cyclopropylmethyl)-6-phenyl- (CA INDEX NAME)




RN 627497-85-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 627497-88-5 CAPLUS

CN Benzonitrile, 3-[[[5-acetyl-2-(cyclopropylmethyl)-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627497-91-0 CAPLUS

CN Benzoic acid, 4-[[[5-acetyl-2-(cyclopropylmethyl)-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627497-94-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(1-methylethyl)-4-(1-naphthalenylamino)-6-phenyl- (CA INDEX NAME)




RN 627497-97-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-difluorophenyl)amino]-2-(1-methylethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-00-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-fluorophenyl)amino]-2-(1-methylethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-03-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(1-methylethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-06-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-dichlorophenyl)amino]-2-(1-methylethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-09-3 CAPLUS

CN Benzoic acid, 4-[[5-acetyl-2,3-dihydro-2-(1-methylethyl)-3-oxo-6-phenyl-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-12-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-fluorophenyl)amino]-2-(1-methylethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-15-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-(1-methylethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-18-4 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2,3-dihydro-2-(1-methylethyl)-3-oxo-6-phenyl-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-21-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[[4-(hydroxymethyl)phenyl]amino]-2-(1-methylethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-24-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-fluorophenyl)amino]-2-(2-hydroxyethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-27-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-30-0 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2,3-dihydro-2-(2-hydroxyethyl)-3-oxo-6-phenyl-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-33-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(2-hydroxyethyl)-4-[[4-(hydroxymethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 627498-36-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-(2-hydroxyethyl)-6-phenyl- (CA INDEX NAME)




RN 627498-39-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-fluorophenyl)-4-[(2-fluorophenyl)amino]-2-(2-hydroxyethyl)- (CA INDEX NAME)




RN 627498-42-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-6-(3-fluorophenyl)-2-(2-hydroxyethyl)- (CA INDEX NAME)




RN 627498-45-7 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-6-(3-fluorophenyl)-2,3-dihydro-2-(2-hydroxyethyl)-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-48-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-fluorophenyl)-2-(2-hydroxyethyl)-4-[[4-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 627498-51-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-6-(3-fluorophenyl)-
2-(2-hydroxyethyl)- (CA INDEX NAME)




RN 627498-54-8 CAPLUS

CN Benzamide, 3-[[5-acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-57-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-4-[[4-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 627498-60-6 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-64-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-(cyclopropylmethyl)-4-[(2-fluorophenyl)amino]- (CA INDEX NAME)




RN 627498-68-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-4-[(3-chlorophenyl)amino]-2-(cyclopropylmethyl)- (CA INDEX NAME)




RN 627498-71-9 CAPLUS

CN Benzamide, 3-[[5-acetyl-2-(cyclopropylmethyl)-6-(3-fluorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-74-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-(cyclopropylmethyl)-6-(3-fluorophenyl)-4-[[4-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 627498-76-4 CAPLUS

CN Benzamide, 3-[[5-acetyl-6-(3-fluorophenyl)-2,3-dihydro-2-(1-methylethyl)-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-79-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-fluorophenyl)-4-[[4-(hydroxymethyl)phenyl]amino]-2-(1-methylethyl)- (CA INDEX NAME)




RN 627498-82-2 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-6-(3-fluorophenyl)-2,3-dihydro-2-(1-methylethyl)-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-84-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-fluorophenyl)-4-[(2-fluorophenyl)amino]-2-(1-methylethyl)- (CA INDEX NAME)




RN 627498-86-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-6-(3-fluorophenyl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 627498-88-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-6-(3-fluorophenyl)-2-(1-methylethyl)- (CA INDEX NAME)




RN 627498-90-2 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-92-4 CAPLUS

CN Benzamide, 3-[[5-acetyl-2-(cyclopropylmethyl)-6-(4-fluorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-94-6 CAPLUS

CN Benzamide, 3-[[5-acetyl-6-(3-chlorophenyl)-2-ethyl-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627498-96-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-[[4-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 627498-98-0 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-6-(3-chlorophenyl)-2-ethyl-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627499-00-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-2-ethyl-4-[(2-fluorophenyl)amino]- (CA INDEX NAME)



RN 627499-02-9 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-6-(3-chlorophenyl)-4-[(2-chlorophenyl)amino]-2-ethyl- (CA INDEX NAME)



RN 627499-04-1 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-fluorophenyl)-4-[[4-

(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 627499-06-3 CAPLUS

CN Benzamide, 3-[[5-acetyl-2-ethyl-6-(3-fluorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627499-08-5 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2-ethyl-6-(3-fluorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627499-10-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(3-fluorophenyl)-4-[(2-fluorophenyl)amino]- (CA INDEX NAME)




RN 627499-12-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-(3-fluorophenyl)- (CA INDEX NAME)




RN 627499-14-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-[[4-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)




RN 627499-16-5 CAPLUS

CN Benzonitrile, 4-[[[5-acetyl-2-ethyl-6-(4-fluorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627499-18-7 CAPLUS

CN Benzamide, 3-[[[5-acetyl-2-ethyl-6-(4-fluorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627499-20-1 CAPLUS

CN Benzonitrile, 3-[[5-acetyl-2-ethyl-6-(4-fluorophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]amino]- (CA INDEX NAME)




RN 627499-22-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-(4-fluorophenyl)-4-[(2-fluorophenyl)amino]- (CA INDEX NAME)




RN 627499-24-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chlorophenyl)amino]-2-ethyl-6-(4-fluorophenyl)- (CA INDEX NAME)




RN 627499-26-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-ethyl-6-(1-naphthalenyl)- (CA INDEX NAME)




RN 627499-28-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,4-difluorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-30-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,4-dichlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-32-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chloro-4-fluorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-34-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chloro-6-methylphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-36-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(5-fluoro-2-methylphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-38-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methyl-5-nitrophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-40-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,3-dimethylphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-42-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,6-difluorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-44-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,5-dimethylphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-46-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,5-difluorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-48-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-fluoro-5-nitrophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-50-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluoro-4-methylphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-52-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,4-difluorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-54-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-bromophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-56-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,3-difluorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-58-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(5-chloro-2-methylphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-60-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chloro-5-methylphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-62-1 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-3-methyl- (CA INDEX NAME)




RN 627499-64-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,4-dichlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-66-5 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-2-chloro- (CA INDEX NAME)




RN 627499-68-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chloro-5-nitrophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-70-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(7-hydroxy-1-naphthalenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-72-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-hydroxy-4-methylphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-74-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-hydroxy-4-nitrophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-76-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-hydroxy-5-methylphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-78-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-hydroxy-5-nitrophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-80-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methoxy-4-nitrophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-82-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-[[4-(trifluoromethoxy)phenyl]amino]- (CA INDEX NAME)




RN 627499-85-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-ethoxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-87-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-methoxy-5-methylphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-89-2 CAPLUS

CN 1-Naphthalenecarbonitrile, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627499-91-6 CAPLUS

CN Benzoic acid, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-5-nitro- (CA INDEX NAME)




RN 627499-93-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-mercaptophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627499-95-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2-chloro-5-methoxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627499-97-2 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-3-methoxy- (CA INDEX NAME)




RN 627499-99-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[3-(1-hydroxyethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 627500-01-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[3-(hydroxymethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 627500-03-2 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-3-hydroxy- (CA INDEX NAME)




RN 627500-05-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[4-(1-hydroxyethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 627500-07-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3,5-dimethoxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627500-09-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,6-dimethylphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627500-11-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[4-(2-hydroxyethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)




RN 627500-13-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-nitrophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-15-6 CAPLUS

CN Benzonitrile, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627500-17-8 CAPLUS

CN Benzamide, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627500-19-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[[2-(hydroxymethyl)phenyl]amino]-6-phenyl- (CA INDEX NAME)



RN 627500-21-4 CAPLUS

CN Benzamide, 2-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)



IT 627500-23-6P, 2-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzenesulfonamide 627500-25-8P, 2-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzonitrile 627500-27-0P, 5-Acetyl-4-[(2,6-dichlorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-29-2P, 5-Acetyl-2-ethyl-4-[(2-nitrophenyl)amino]-6-phenylpyridazin-3(2H)-one 627500-31-6P, 5-Acetyl-4-[(5-chloro-2-hydroxyphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-33-8P, 5-Acetyl-4-[(3-chloro-4-hydroxyphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-35-0P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzenesulfonamide 627500-37-2P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-1-naphthoic acid 627500-39-4P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-4-methoxybenzamide 627500-41-8P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-2-methoxybenzoic acid


627500-43-0P, 5-Acetyl-2-ethyl-4-[(3-fluoro-4-hydroxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627500-45-2P, 5-Acetyl-2-ethyl-4-[(5-fluoro-2-hydroxyphenyl)amino]-6-phenylpyridazin-3(2H)-one 627500-47-4P, 5-Acetyl-2-ethyl-4-[(6-hydroxy-1-naphthyl)amino]-6-phenylpyridazin-3(2H)-one 627500-49-6P, 5-Acetyl-2-ethyl-4-[(3-fluoro-2-methylphenyl)amino]-6-phenylpyridazin-3(2H)-one 627500-51-0P, 5-Acetyl-2-ethyl-4-[(2-hydroxy-1-naphthyl)amino]-6-phenylpyridazin-3(2H)-one 627500-53-2P, 5-Acetyl-2-ethyl-4-[(5-hydroxy-1-naphthyl)amino]-6-phenylpyridazin-3(2H)-one 627500-55-4P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-3-fluorobenzoic acid 627500-57-6P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-N,N-dimethylbenzamide 627500-59-8P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-N-methylbenzamide 627500-60-1P, 5-Acetyl-2-ethyl-4-[(4-nitro-1-naphthyl)amino]-6-phenylpyridazin-3(2H)-one 627500-61-2P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-2-fluorobenzoic acid 627500-62-3P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-3-chlorobenzoic acid 627500-63-4P, 5-Acetyl-4-[(3-chloro-2-methylphenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-64-5P, Methyl 4-[(5-acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]benzoate 627500-65-6P, 4-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-5-chloro-2-methoxybenzoic acid 627500-66-7P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-4-methylbenzamide 627500-67-8P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-4-chlorobenzamide 627500-68-9P, 5-Acetyl-4-[(4-chloro-1-naphthyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-69-0P, 5-Acetyl-2-ethyl-6-phenyl-4-[(2,4,6-trifluorophenyl)amino]pyridazin-3(2H)-one 627500-70-3P, 5-Acetyl-2-ethyl-6-phenyl-4-[(3,4,5-trifluorophenyl)amino]pyridazin-3(2H)-one 627500-71-4P, 3-[(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)amino]-4-chlorobenzoic acid 627500-72-5P, 5-Acetyl-4-[[4-(aminomethyl)phenyl]amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-73-6P, 5-Acetyl-4-[[4-(2-aminoethyl)phenyl]amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-74-7P, 1-Ethyl-5-[(3-fluorophenyl)amino]-6-oxo-3-phenyl-4-carboxy-1,6-dihydropyridazine 627500-75-8P, 5-[(3-Chlorophenyl)amino]-1-ethyl-6-oxo-3-phenyl-4-carboxy-1,6-dihydropyridazine 627500-76-9P, 1-Ethyl-5-[(3-fluorophenyl)amino]-6-oxo-3-phenyl-4-methoxycarbonyl-1,6-dihydropyridazine 627500-77-0P, 5-[(3-Chlorophenyl)amino]-1-ethyl-6-oxo-3-phenyl-4-isopropoxycarbonyl-1,6-dihydropyridazine 627500-78-1P, 5-[(3-Chlorophenyl)amino]-1-ethyl-6-oxo-3-phenyl-4-ethoxycarbonyl-1,6-dihydropyridazine 627500-79-2P, 5-[(3-Chlorophenyl)amino]-1-ethyl-6-oxo-3-phenyl-4-benzyloxycarbonyl-1,6-dihydropyridazine 627500-82-7P, 5-Acetyl-4-[(3-chlorophenyl)amino]-2-[2-(dimethylamino)ethyl]-6-phenylpyridazin-3(2H)-one 627500-84-9P, 5-Acetyl-2-cyclobutyl-4-[(3,5-dichlorophenyl)amino]-6-phenylpyridazin-3(2H)-one 627500-85-0P, 5-Acetyl-4-[(3-chlorophenyl)(2-hydroxyethyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-86-1P, N-(5-Acetyl-2-ethyl-3-oxo-6-phenyl-2,3-dihydropyridazin-4-yl)-N-(3-chlorophenyl)urea 627500-88-3P, 4-[(3-Chlorophenyl)amino]-5-[(dimethylamino)acetyl]-2-ethyl-6-phenylpyridazin-3(2H)-one 627500-90-7P, 4-[[2-Ethyl-5-(methoxyacetyl)-6-phenyl-3-oxo-2,3-dihydropyridazin-4-yl]amino]-benzoic acid 627500-92-9P, 5-[(3-Cyanophenyl)amino]-1-ethyl-6-oxo-3-phenyl-1,6-dihydropyridazine-4-carboxamide 627500-95-2P, 5-[(3-Cyanophenyl)amino]-1-ethyl-6-oxo-3-phenyl-4-carboxy-1,6-dihydropyridazine 627500-99-6P, 3-[4-Acetyl-5-[(3,5-difluorophenyl)amino]-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]-benzoic

acid 627501-04-6P, 3-[4-Acetyl-5-[(3,5-difluorophenyl)amino]-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile 627501-06-8P, N-[3-[4-Acetyl-5-[(3,5-difluorophenyl)amino]-1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl]phenyl]urea 627501-08-0P, 5-Acetyl-4-[(3-chlorophenyl)amino]-6-phenylpyridazin-3(2H)-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE4 inhibitor; preparation of pyridazinones as PDE4 inhibitors)


RN 627500-23-6 CAPLUS

CN Benzenesulfonamide, 2-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627500-25-8 CAPLUS

CN Benzonitrile, 2-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627500-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(2,6-dichlorophenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627500-29-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-nitrophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-31-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(5-chloro-2-hydroxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627500-33-8 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chloro-4-hydroxyphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627500-35-0 CAPLUS

CN Benzenesulfonamide, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627500-37-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]- (CA INDEX NAME)




RN 627500-39-4 CAPLUS

CN Benamide, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-4-methoxy- (CA INDEX NAME)




RN 627500-41-8 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-2-methoxy- (CA INDEX NAME)




RN 627500-43-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluoro-4-hydroxyphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-45-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(5-fluoro-2-hydroxyphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-47-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(6-hydroxy-1-naphthalenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-49-6 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(3-fluoro-2-methylphenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-51-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(2-hydroxy-1-naphthalenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-53-2 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(5-hydroxy-1-naphthalenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-55-4 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-3-fluoro- (CA INDEX NAME)




RN 627500-57-6 CAPLUS

CN Benzamide, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-N,N-dimethyl- (CA INDEX NAME)




RN 627500-59-8 CAPLUS

CN Benzamide, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-N-methyl- (CA INDEX NAME)




RN 627500-60-1 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-4-[(4-nitro-1-naphthalenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-61-2 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-2-fluoro- (CA INDEX NAME)




RN 627500-62-3 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-3-chloro- (CA INDEX NAME)




RN 627500-63-4 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chloro-2-methylphenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627500-64-5 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-, methyl ester (CA INDEX NAME)




RN 627500-65-6 CAPLUS

CN Benzoic acid, 4-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-5-chloro-2-methoxy- (CA INDEX NAME)




RN 627500-66-7 CAPLUS

CN Benzamide, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-4-methyl- (CA INDEX NAME)




RN 627500-67-8 CAPLUS

CN Benzamide, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-4-chloro- (CA INDEX NAME)




RN 627500-68-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(4-chloro-1-naphthalenyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627500-69-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-[(2,4,6-trifluorophenyl)amino]- (CA INDEX NAME)




RN 627500-70-3 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-ethyl-6-phenyl-4-[(3,4,5-trifluorophenyl)amino]- (CA INDEX NAME)




RN 627500-71-4 CAPLUS

CN Benzoic acid, 3-[(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)amino]-4-chloro- (CA INDEX NAME)



RN 627500-72-5 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-4-[[4-(aminomethyl)phenyl]amino]-2-ethyl-6-phenyl- (CA INDEX NAME)



RN 627500-73-6 CAPLUS


CN 3(2H)-Pyridazinone, 5-acetyl-4-[[4-(2-aminoethyl)phenyl]amino]-2-ethyl-6-

phenyl- (CA INDEX NAME)




RN 627500-74-7 CAPLUS

CN 4-Pyridazinecarboxylic acid, 1-ethyl-5-[(3-fluorophenyl)amino]-1,6-dihydro-6-oxo-3-phenyl- (CA INDEX NAME)




RN 627500-75-8 CAPLUS

CN 4-Pyridazinecarboxylic acid, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl- (CA INDEX NAME)




RN 627500-76-9 CAPLUS

CN 4-Pyridazinecarboxylic acid, 1-ethyl-5-[(3-fluorophenyl)amino]-1,6-dihydro-6-oxo-3-phenyl-, methyl ester (CA INDEX NAME)




RN 627500-77-0 CAPLUS

CN 4-Pyridazinecarboxylic acid, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl-, 1-methylethyl ester (CA INDEX NAME)




RN 627500-78-1 CAPLUS

CN 4-Pyridazinecarboxylic acid, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl-, ethyl ester (CA INDEX NAME)




RN 627500-79-2 CAPLUS

CN 4-Pyridazinecarboxylic acid, 5-[(3-chlorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl-, phenylmethyl ester (CA INDEX NAME)




RN 627500-82-7 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-2-[2-(dimethylamino)ethyl]-6-phenyl- (CA INDEX NAME)





RN 627500-84-9 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-cyclobutyl-4-[(3,5-dichlorophenyl)amino]-6-phenyl- (CA INDEX NAME)




RN 627500-85-0 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)(2-hydroxyethyl)amino]-2-ethyl-6-phenyl- (CA INDEX NAME)




RN 627500-86-1 CAPLUS

CN Urea, N-(5-acetyl-2-ethyl-2,3-dihydro-3-oxo-6-phenyl-4-pyridazinyl)-N-(3-chlorophenyl)- (CA INDEX NAME)




RN 627500-88-3 CAPLUS

CN 3(2H)-Pyridazinone, 4-[(3-chlorophenyl)amino]-5-[(dimethylamino)acetyl]-2-ethyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 627500-90-7 CAPLUS

CN Benzoic acid, 4-[[2-ethyl-2,3-dihydro-5-(methoxyacetyl)-3-oxo-6-phenyl-4-pyridazinyl]amino]- (9CI) (CA INDEX NAME)




RN 627500-92-9 CAPLUS

CN 4-Pyridazinecarboxamide, 5-[(3-cyanophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl- (CA INDEX NAME)




RN 627500-95-2 CAPLUS

CN 4-Pyridazinecarboxylic acid, 5-[(3-cyanophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-phenyl- (CA INDEX NAME)




RN 627500-99-6 CAPLUS

CN Benzoic acid, 3-[4-acetyl-5-[(3,5-difluorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-pyridazinyl]- (CA INDEX NAME)




RN 627501-04-6 CAPLUS

CN Benzonitrile, 3-[4-acetyl-5-[(3,5-difluorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-pyridazinyl]- (CA INDEX NAME)




RN 627501-06-8 CAPLUS

CN Urea, [3-[4-acetyl-5-[(3,5-difluorophenyl)amino]-1-ethyl-1,6-dihydro-6-oxo-3-pyridazinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 627501-08-0 CAPLUS
 CN 3(2H)-Pyridazinone, 5-acetyl-4-[(3-chlorophenyl)amino]-6-phenyl- (CA
 INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:566668 CAPLUS Full-text
 DOCUMENT NUMBER: 131:286474
 TITLE: New synthesis of differently fused
 pyridazinoquinolines
 AUTHOR(S): Dal Piaz, Vittorio; Giovannoni, Maria Paola; Ciciani,
 Giovanna; Vergelli, Claudia
 CORPORATE SOURCE: Dipartimento Scienze Farmaceutiche, Univ. Firenze,
 Florence, I-50121, Italy
 SOURCE: Synlett (1999), (9), 1453-1455
 CODEN: SYNLES; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:286474
 AB Treatment of 4-chloro- and 4-(methylthio)-5-acetyl-2-methyl-6-(2-
 nitrophenyl)-3(2H)-pyridazinone with SnCl₂/HCl afforded pyridazino[4,3-
 c]quinolinones, whereas a pyridazino[4,5-b]quinolinone was prepared by
 reduction of 5-acetyl-4-anilino-6-phenyl-3(2H)-pyridazinone with NaBH₄,
 followed by dehydration with polyphosphoric acid.
 IT 246178-47-2F
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyridazinoquinolines)
 RN 246178-47-2 CAPLUS
 CN 3(2H)-Pyridazinone, 5-(1-hydroxyethyl)-2-methyl-6-phenyl-4-(phenylamino)-
 (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:304425 CAPLUS Full-text
 DOCUMENT NUMBER: 130:352238
 TITLE: Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential
 substrate for new aldose reductase inhibitors
 AUTHOR(S): Costantino, Luca; Rastelli, Giulio; Gamberini, M.
 Cristina; Giovannoni, M. Paola; Dal Piaz, Vittorio;
 Vianello, Paola; Barlocco, Daniela
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Via G. Campi
 183, Modena, 41100, Italy
 SOURCE: Journal of Medicinal Chemistry (1999), 42(11),
 1894-1900
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The isoxazolo[3,4-d]pyridazin-7(6H)-one I (R = Ph, Me, 4-ClC₆H₄, etc.) and its corresponding open derivs. 5-acetyl-4-amino(4-nitro)-6-substituted- 3(2H)-pyridazinones II (X = NH₂, NO₂) were used as simplified substrates for the synthesis of new aldose reductase inhibitors with respect to the previously reported 5,6-dihydrobenzo[h]cinnolin-3(2H)-one-2 acetic acid III. Moreover, a few derivs. lacking the 5-acetyl group were prepared Several compds. derived from I displayed inhibitory properties comparable to those of Sorbinil. In this class the presence at position 6 of a Ph carrying an electron-withdrawing substituent proved to be beneficial, independently from its position on the ring I [R = 4-ClC₆H₄, 2-, 3-, 4-O₂NC₆H₄, R' = (CH₂)_nCO₂H, n = 1]. Acetic acid derivs. were more effective than propionic and butyric analogs. On the contrary, all the monocyclic compds. IV (R = Ph, Me, n = 1-3), V (R = Ph, CH₂Ph, 4-ClC₆H₄, etc.), and VI (R = H, CH₂Ph, CH₂CH₂Ph, CH₂CH₂-pyrid-2-yl) were either inactive or only weakly active. The 3-methyl-4-(p-chlorophenyl)isoxazolo[3,4-d]pyridazin-7(6H)-one acetic acid, which proved to

be the most potent derivative, was also investigated in mol. modeling studies, to assess possible similarities in its interaction with the enzyme, with respect to the model III.


IT 224956-78-9P 224956-82-5P 224956-83-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and aldose reductase inhibitory activity of isoxazolopyridazinones)


RN 224956-78-9 CAPLUS

CN 1(6H)-Pyridazineacetic acid, 4-acetyl-6-oxo-3-phenyl-5-(phenylamino)- (CA INDEX NAME)




RN 224956-82-5 CAPLUS

CN 1(6H)-Pyridazineacetic acid, 4-acetyl-5-[(4-chlorophenyl)amino]-6-oxo-3-phenyl- (CA INDEX NAME)



RN 224956-83-6 CAPLUS

CN 1(6H)-Pyridazineacetic acid, 4-acetyl-5-[(4-bromophenyl)amino]-6-oxo-3-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1991:441291 CAPLUS Full-text
 DOCUMENT NUMBER: 115:41291

TITLE: 5-Acyl-6-aryl-4-nitro-3(2H)pyridazinones and related
4-amino compounds: synthesis and pharmacological
evaluation

AUTHOR(S): Dal Piaz, Vittorio; Ciciani, Giovanna; Turco,
Giovanni; Giovannoni, Maria Paola; Miceli, Mauro;
Pirisino, Renato; Perretti, Mauro


CORPORATE SOURCE: Dip. Sci. Farm., Univ. Firenze, Florence, 50121, Italy

SOURCE: Journal of Pharmaceutical Sciences (1991), 80(4),
341-8
CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB Several 4-nitro- and 4-amino-5-acyl-6-aryl-3(2H)-pyridazinones were prepared and their in vitro and ex vivo antiaggregatory properties were evaluated. 4-Nitro derivs. generally showed good activity in vitro towards arachidonic acid (AA)-induced human blood platelet aggregation. The 4-amino compound (I, R1 = R3 = Me; R2 = Ph; R4 = NH2) which has weak in vitro activity, exhibited antiplatelet activity, particularly on adenosine diphosphate (ADP)-induced aggregation ex vivo in rabbit. Moreover, the same compound was active in platelet-activating factors (PAF)-induced rat paw hyperalgesia and to be endowed with low acute oral toxicity. The 4-amino derivs. and the other pyridazinones administered orally to rats were also more potent anti-inflammatory agents than acetylsalicylic acid. I (R1 = R3 = Me; R2 = Ph; R4 = NO2 or NH2) tested in vitro on lipopolysaccharide (LPS)-stimulated rat peritoneal macrophages, were active in the inhibition of prostaglandin E2 (PGE2) production and interleukin-1 activity. Structure-activity relation studies in the series of antiaggregating pyridazinones showed the primary importance of the nitro and acetyl substituents at positions 4 and 5, resp. Hydrophobic substituents at position 2 were also required for better activity.

IT 134843-07-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and blood platelet aggregation inhibitory and antiinflammatory activities of)


RN 134843-07-5 CAPLUS

CN 3(2H)-Pyridazinone, 5-acetyl-2-methyl-6-phenyl-4-(phenylamino)- (CA INDEX NAME)



=> d que 16

L1 STR



VAR G1=H/15/18/22/AK/CY

VAR G2=NH2/24/27

VAR G4=H/OH/29/NH2/24/27/CN/AK/CY

VAR G5=35/32

VAR G6=AK/CY

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 16

CONNECT IS E1 RC AT 20

CONNECT IS E1 RC AT 25

CONNECT IS E1 RC AT 26

CONNECT IS E1 RC AT 28

CONNECT IS E1 RC AT 30

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 11

GGCAT IS UNS AT 35

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L3 927 SEA FILE=REGISTRY SSS FUL L1

L4 9 SEA FILE=CAPLUS ABB=ON PLU=ON L3

L5 6 SEA FILE=CAPLUS ABB=ON PLU=ON L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

L6 3 SEA FILE=CAPLUS ABB=ON PLU=ON L4 NOT L5

=> fil cap dissabs confsci wpix

FILE 'CAPLUS' ENTERED AT 11:29:39 ON 14 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DISSABS' ENTERED AT 11:29:39 ON 14 MAR 2008

COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'CONFSCI' ENTERED AT 11:29:39 ON 14 MAR 2008

COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'WPIX' ENTERED AT 11:29:39 ON 14 MAR 2008
 COPYRIGHT (C) 2008 THE THOMSON CORPORATION

=> d que 1118
 'LL18' IS NOT VALID HERE
 For an explanation, enter "HELP DISPLAY QUERY".

=> dup rem 16 118
 PROCESSING COMPLETED FOR L6
 PROCESSING COMPLETED FOR L18
 L19 18 DUP REM L6 L18 (7 DUPLICATES REMOVED)
 ANSWERS '1-17' FROM FILE CAPLUS
 ANSWER '18' FROM FILE WPIX

=> d 119 ibib abs tot



L19 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2005:1354871 CAPLUS Full-text
 DOCUMENT NUMBER: 144:88299
 TITLE: Preparation of pyridazin-3(2H)-one derivatives as PDE4
 inhibitors for the treatment of pathological diseases
 INVENTOR(S): Aguilar Izquierdo, Nuria; Carrascal Riera, Marta; Dal
 Piazz, Vittorio; Gracia Ferrer, Jordi; Lumeras Amador,
 Wenceslao; Masdeu Margalef, Maria del Carmen;
 Warrellow, Graham
 PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain
 SOURCE: PCT Int. Appl., 173 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123693	A1	20051229	WO 2005-EP6712	20050621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2251867	A1	20060501	ES 2004-1512	20040621
ES 2251867	B1	20070616		
AU 2005254704	A1	20051229	AU 2005-254704	20050621
CA 2570196	A1	20051229	CA 2005-2570196	20050621
EP 1781621	A1	20070509	EP 2005-752744	20050621
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1976904	A	20070606	CN 2005-80019333	20050621
BR 2005011344	A	20071204	BR 2005-11344	20050621
JP 2008503531	T	20080207	JP 2007-517186	20050621

10/578,594

March 14, 2008

IN 2006DN07027	A	20070831	IN 2006-DN7027	20061123
MX 2006PA14562	A	20070724	MX 2006-PA14562	20061213
NO 2007000319	A	20070306	NO 2007-319	20070117
KR 2007036137	A	20070402	KR 2007-701315	20070118
PRIORITY APPLN. INFO.:			ES 2004-1512	A 20040621
			WO 2005-EP6712	W 20050621
OTHER SOURCE(S):		CASREACT 144:88299; MARPAT 144:88299		
GI				



AB The invention relates to new therapeutically useful pyridazin-3(2H)-one derivs. I [wherein R1 = H or (un)substituted alk(en/yn)yl; R2 = (un)substituted heteroaryl; R3 = H, alkyl aryl, etc., R4 = (un)substituted (hetero)aryl, and pharmaceutically acceptable salts or N-oxides thereof], to their preps., and to pharmaceutical compns. containing them. These compds. are potent inhibitors of phosphodiesterase 4 (PDE4), and are thus useful in the treatment, prevention or suppression of pathol. conditions, diseases and disorders known to be susceptible of being improved by inhibition of PDE4, such as asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease. For example, II, which had an IC50 of 0.07 nM in the PDE4 inhibition assay, was synthesized by esterification of the corresponding acid (preparation given) with chloromethyl pivalate.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 2005:1350734 CAPLUS Full-text
 DOCUMENT NUMBER: 144:88298
 TITLE: Preparation of pyridazin-3(2H)-one derivatives as PDE4 inhibitors for the treatment of pathological diseases
 INVENTOR(S): Buil Alberro, Maria Antonia; Dal Piaz, Vittorio; Garrido Rubio, Yolanda; Gracia Ferrer, Jordi; Pages Santacana, Lluís Miquel; Taltavull Moll, Joan
 PATENT ASSIGNEE(S): Almirall Prodesfarma, SA, Spain
 SOURCE: PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005123692	A1	20051229	WO 2005-EP6304	20050613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

ES 2251866 A1 20060501 ES 2004-1500 20040618

ES 2251866 B1 20070616

AU 2005254659 A1 20051229 AU 2005-254659 20050613

CA 2570170 A1 20051229 CA 2005-2570170 20050613

EP 1758869 A1 20070307 EP 2005-751683 20050613

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
 HR, LV, MK, YU

CN 1964952 A 20070516 CN 2005-80018773 20050613

BR 2005011383 A 20071226 BR 2005-11383 20050613

JP 2008502628 T 20080131 JP 2007-515846 20050613

MX 2006PA13593 A 20070315 MX 2006-PA13593 20061123

IN 2006DN07020 A 20070831 IN 2006-DN7020 20061123

NO 2007000321 A 20070312 NO 2007-321 20070117

KR 2007029808 A 20070314 KR 2007-701216 20070117

PRIORITY APPLN. INFO.:



ES 2004-1500 A 20040618

WO 2005-EP6304 W 20050613

OTHER SOURCE(S):

CASREACT 144:88298; MARPAT 144:88298

GI



AB The invention relates to new therapeutically useful pyridazin-3(2H)-one derivs. I [wherein R1 = H or (un)substituted alk(en/yn)yl; R2 = (un)substituted heteroaryl; R3 = H or alkylcarbonyl; R4 = H, alkyl, aryl, etc., and pharmaceutically acceptable salts or N-oxides thereof], to their prepn.s., and to pharmaceutical compns. containing them. These compds. are potent inhibitors of phosphodiesterase 4 (PDE4), and are thus useful in the treatment, prevention or suppression of pathol. conditions, diseases and disorders known to be susceptible of being improved by inhibition of PDE4, such as asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease. For example, II, which had an IC50 of 0.36 nM in the PDE4 inhibition assay, was synthesized by

10/578,594

March 14, 2008

esterification of the corresponding acid (preparation given) with chloromethyl
2,2-dimethylbutyrate.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2005:472131 CAPLUS Full-text

DOCUMENT NUMBER: 143:26620

TITLE: Preparation of pyridazin-3(2H)-ones and their use as
PDE4 inhibitors

INVENTOR(S): Dal Piaz, Vittorio; Aguilar Izquierdo, Nuria;
Buil Albero, Maria Antonia; Garrido Rubio,
Yolanda; Giovannoni Maria, Paola; Gracia Ferrer,
Jordi; Lumeras Amador, Wenceslao; Vergelli, Claudia

PATENT ASSIGNEE(S): Almirall Prodesfarma, S. A., Spain

SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049581	A1	20050602	WO 2004-EP12604	20041108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2232306	A1	20050516	ES 2003-2613	20031110
ES 2232306	B1	20060801		
AU 2004291282	A1	20050602	AU 2004-291282	20041108
CA 2545193	A1	20050602	CA 2004-2545193	20041108
EP 1682519	A1	20060726	EP 2004-797700	20041108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1878759	A	20061213	CN 2004-80033113	20041108
BR 2004016212	A	20070102	BR 2004-16212	20041108
JP 2007510689	T	20070426	JP 2006-538762	20041108
IN 2006DN01703	A	20070831	IN 2006-DN1703	20060329
MX 2006PA05101	A	20060714	MX 2006-PA5101	20060504
KR 2007001907	A	20070104	KR 2006-711454	20060609
NO 2006002726	A	20060612	NO 2006-2726	20060612
US 2007197536	A1	20070823	US 2007-578594	20070215
PRIORITY APPLN. INFO.:			ES 2003-2613	A 20031110
			WO 2004-EP12604	W 20041108

OTHER SOURCE(S): MARPAT 143:26620

GI



AB Title compds. I [R1-2 = H, acyl, alkoxycarbonyl, etc.; R3 = mono/polycyclic (hetero)aryl, etc.; R4 = H, OH, alkoxy, amino, etc.; R5 = carboxy, mono/polycyclic (hetero)aryl, etc.] are prepared For instance, 1-Ethyl-3-(4-fluorophenyl)-6-oxo-5-((pyridin-3-yl)amino)-1,6- dihydropyridazine-4-carbonitrile (II) is prepared from 5-Amino-1-ethyl-3-(4-fluorophenyl)-6-oxo-1,6-dihydropyridazine-4- carbonitrile (preparation given) and 3-bromopyridine. II has IC50 = 5.4 for PDE4. I are useful for the treatment of asthma, COPD, etc.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2003:931340 CAPLUS Full-text

DOCUMENT NUMBER: 140:5060

TITLE: Preparation of pyridazin-3(2H)-ones as Phosphodiesterase 4 (PDE4) inhibitors

INVENTOR(S): Dal Piaz, Vittorio; Giovannoni, Maria Paola; Vergelli, Claudia; Aguilar, Izquierdo Nuria

PATENT ASSIGNEE(S): Almirall Prodesfarma Sa, Spain; Aguilar Izquierdo, Nuria

SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097613	A1	20031127	WO 2003-EP5056	20030514
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
ES 2195785	A1	20031201	ES 2002-1111	20020516
ES 2195785	B1	20050316		
CA 2485896	A1	20031127	CA 2003-2485896	20030514
AU 2003236648	A1	20031202	AU 2003-236648	20030514
EP 1503992	A1	20050209	EP 2003-735387	20030514
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
BR 2003010106	A	20050222	BR 2003-10106	20030514

10/578,594

March 14, 2008

JP 2005533024	T	20051104	JP 2004-505346	20030514
NZ 536604	A	20060728	NZ 2003-536604	20030514
MX 2004PA11209	A	20050214	MX 2004-PA11209	20041111
ZA 2004009173	A	20050729	ZA 2004-9173	20041111
IN 2004DN03570	A	20050401	IN 2004-DN3570	20041116
NO 2004005461	A	20050119	NO 2004-5461	20041215
US 2006052379	A1	20060309	US 2005-513219	20050629
PRIORITY APPLN. INFO.:			ES 2002-1111	A 20020516
			WO 2003-EP5056	W 20030514
OTHER SOURCE(S):	MARPAT 140:5060			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = H, acyl, alkoxy carbonyl, monoalkyl/dialkyl/carbamoyl, (un)substituted alkyl, (CH₂)_n-R₆; n = 0 to 4; R₆ = cycloalkyl, (un)substituted aryl, 3- to 7-membered heterocyclyl; R₂ = R₁, (un)substituted alkyl; R₃, R₅ = independently (un)substituted monocyclic or bicyclic aryl; R₄ = H, OH and derivs., NH₂ and derivs., (un)substituted alkyl, (CH₂)_n-R₆; with the proviso that when R₂ = H and R₃, R₄ = unsubstituted Ph, R₁ is not methyl; and their pharmaceutical acceptable salts] were prepared as potent and selective inhibitors of Phosphodiesterase 4 (PDE4). Four pharmaceutical compns. are given. For example, II was prepared by hydrogenation of 6-ethyl-3-methyl-4- phenylisoxazolo[3,4-d]pyridazin-7(6H)-one over Pd/C in ethanol, and reaction of the resulting 4-aminopyridazinone with 3-fluorophenylboronic acid in the presence of Cu(OAc)₂/TEA/mol. sieves/CH₂Cl₂. Selected I exhibited an IC₅₀ value < 20 nM for the inhibition of PDE4. I and their pharmaceutical compns. are useful for prevention and treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease (no data).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 1999:113680 CAPLUS Full-text

DOCUMENT NUMBER: 130:153661

TITLE: Preparation of 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazines as phosphodiesterase IV inhibitors.

INVENTOR(S): Gracia Ferrer, Jordi; Crespo Crespo, Ma. Isabel; Vega Noverola, Armando; Fernandez Garcia, Andres

PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906404	A1	19990211	WO 1998-EP4340	19980713
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				

10/578,594

March 14, 2008

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

ES 2137113	A1	19991201	ES 1997-1670	19970729
ES 2137113	B1	20000916		
CA 2298935	A1	19990211	CA 1998-2298935	19980713
AU 9888612	A	19990222	AU 1998-88612	19980713
AU 737709	B2	20010830		
EP 1001955	A1	20000524	EP 1998-940218	19980713
EP 1001955	B1	20011017		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO


TR 200000243	T2	20000721	TR 2000-243	19980713
BR 9810829	A	20000725	BR 1998-10829	19980713
EE 200000052	A	20001016	EE 2000-52	19980713
EE 4313	B1	20040615		
NZ 502356	A	20010330	NZ 1998-502356	19980713
HU 2000004708	A2	20010730	HU 2000-4708	19980713
JP 2001512121	T	20010821	JP 2000-505162	19980713
AT 207069	T	20011115	AT 1998-940218	19980713
ES 2162466	T3	20011216	ES 1998-940218	19980713
PT 1001955	T	20020228	PT 1998-940218	19980713
CZ 290208	B6	20020612	CZ 2000-333	19980713
RU 2202552	C2	20030420	RU 2000-104863	19980713
CN 1135230	B	20040121	CN 1998-808121	19980713
IL 134081	A	20040208	IL 1998-134081	19980713
SK 284046	B6	20040803	SK 2000-86	19980713
PL 191031	B1	20060331	PL 1998-338214	19980713
ZA 9806248	A	19990205	ZA 1998-6248	19980714
TW 542837	B	20030721	TW 1998-87111560	19980716
IN 1998DE02173	A	20070309	IN 1998-DE2173	19980724
NO 2000000394	A	20000327	NO 2000-394	20000126
NO 315118	B1	20030714		
MX 200000910	A	20011127	MX 2000-910	20000126
BG 104112	A	20010131	BG 2000-104112	20000127
BG 64448	B1	20050228		
US 6407108	B1	20020618	US 2000-496019	20000128
HK 1024914	A1	20020222	HK 2000-103595	20000615
US 2002183326	A1	20021205	US 2002-38777	20020108

PRIORITY APPLN. INFO.:

ES 1997-1670	A	19970729
WO 1998-EP4340	W	19980713
US 2000-496019	A1	20000128

OTHER SOURCE(S): MARPAT 130:153661

GI



AB Title compds. [I; R1 = H, (CH₂)_mY; m = 0-4; Y = alkyl, haloalkyl, alkoxy, alkoxy carbonyl, C3-C7 cycloalkyl, norbornyl, phenylalkenyl, (halo-substituted) aryl; R2 = (substituted) aryl; R3 = H, halo, alkyl], were prepared Thus, 2-

benzoylnicotinic acid tert-butoxycarbonylhydrazine was refluxed with POCl₃ to give 80% 5-chloro-8-phenylpyrido[2,3- d]pyridazine. This was refluxed with tert-Bu carbazate in THF to give 5-tert-butyloxycarbonylhydrazino-8-phenylpyrido[2,3-d]pyridazine, which was stirred with HCl in EtOH to give 92% 5-hydrazino-8-phenylpyrido[2,3- d]pyridazinedihydrochloride. The latter was stirred with Et₃N and pivaloyl chloride in CH₂Cl₂ to give 69% 3-tert-butyl-6-phenyl-1,2,4- triazolo[4,3-b]pyrido[3,2-d]pyridazine. Tested I inhibited PDE IV with IC₅₀ = 0.04-3 μM.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:689152 CAPLUS Full-text

DOCUMENT NUMBER: 147:180550

TITLE: 4-Amino-5-vinyl-3(2H)-pyridazinones and analogues as potent antinociceptive agents: Synthesis, SARs, and preliminary studies on the mechanism of action

AUTHOR(S): Vergelli, Claudia; Giovannoni, Maria Paola; Pieretti, Stefano; Di Giannuario, Amalia; Dal Piaz, Vittorio; Biagini, Pierfrancesco; Biancalani, Claudio; Graziano, Alessia; Cesari, Nicoletta

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Florence, Sesto Fiorentino, 50019, Italy

SOURCE: Bioorganic & Medicinal Chemistry (2007), 15(16), 5563-5575

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:180550

AB A series of 4-amino-5-vinyl-3(2H)-pyridazinones and analogs were synthesized and their antinociceptive effect was evaluated in the mouse abdominal constriction model. Several of the novel compds. showed ED₅₀ values in the range 6-20 mg/kg/s.c. and demonstrated to be able to completely protect all the treated animals from the effect of the noxious stimulus at 30 mg/kg/s.c. SAR studies confirmed the essential role played by an amino or substituted amino function at position 4 and by a vinyl group at position 5 of the diazine system.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:778363 CAPLUS Full-text

DOCUMENT NUMBER: 147:249853

TITLE: Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE₄ inhibitors

AUTHOR(S): Giovannoni, Maria P.; Cesari, Nicoletta; Graziano, Alessia; Vergelli, Claudia; Biancalani, Claudio; Biagini, Pierfrancesco; Dal Piaz, Vittorio

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Florence, 50019, Italy

SOURCE: Journal of Enzyme Inhibition and Medicinal Chemistry (2007), 22(3), 309-318

CODEN: JEIMAZ; ISSN: 1475-6366


PUBLISHER: Informa Healthcare

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:249853

GI



I

AB A series of pyrrolo[2,3-d]pyridazinones was synthesized and tested for their inhibitory activity on PDE4 subtypes A, B and D and selectivity toward Rolipram high affinity binding site (HARBS). New agents with interesting profile were reported; in particular compound 9e (I) showed a good PDE4 subtype selectivity, being 8 times more potent ($IC_{50} = 0.32 \mu M$) for PDE4B (anti-inflammatory) than for PDE4D ($IC_{50} = 2.5 \mu M$), generally considered the subtype responsible for emesis. Moreover the ratio HARBS/PDE4B was particularly favorable for 9e (147), suggesting that the best arranged groups around the pyrrolopyridazinone core are an iso-Pr at position-1, an ethoxycarbonyl at position-2, together with an Et group at position-6. For compds. 8 and 15a the ability to inhibit $TNF\alpha$ production in PBMC was evaluated and the results are consistent with their PDE4 inhibitory activity.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:761996 CAPLUS Full-text

DOCUMENT NUMBER: 145:356751

TITLE: Novel Pyrazolopyrimidopyridazinones with Potent and Selective Phosphodiesterase 5 (PDE5) Inhibitory Activity as Potential Agents for Treatment of Erectile Dysfunction

AUTHOR(S): Giovannoni, Maria Paola; Vergelli, Claudia; Biancalani, Claudio; Cesari, Nicoletta; Graziano, Alessia; Biagini, Pierfrancesco; Gracia, Jordi; Gavalda, Amadeu; Dal Piaz, Vittorio

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Firenze, Florence, 50019, Italy

SOURCE: Journal of Medicinal Chemistry (2006), 49(17), 5363-5371

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:356751

GI



AB Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones and their analogs, potentially useful for the treatment of erectile dysfunction, were synthesized and evaluated as inhibitors of phosphodiesterase 5 (PDE5). Several compds. showed IC₅₀ values in the low nanomolar range, and in particular the (oxobutyl)pyrazolopyrimidopyridazinone I which displayed high potency toward PDE5 and high selectivity vs. PDE6 and appeared to be a very promising new lead both in comparison with the potent but not selective sildenafil and in comparison with some analogs previously reported. SAR studies in this triheterocyclic scaffold showed that the best arranged groups are a Me at C-1, a benzyl at C-3, a Ph at C-9, and a linear four-carbon chain at C-6.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:651000 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 146:176551

TITLE: Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors

AUTHOR(S): Pieretti, Stefano; Dominici, Luigi; Di Giannuario, Amalia; Cesari, Nicoletta; Dal Piaz, Vittorio

CORPORATE SOURCE: Department of Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy

SOURCE: Life Sciences (2006), 79(8), 791-800
CODEN: LIFSAK; ISSN: 0024-3205

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Phosphodiesterase 4 (PDE4) inhibitors are effective anti-inflammatory drugs, although some adverse effects are observed in animals and humans. These effects have forced researchers to find new PDE4 inhibitors with less adverse effects. We recently reported the synthesis of novel heterocyclic-fused pyridazinones that inhibit PDE4. As a first step in the study of the anti-inflammatory properties of these compds., we studied the effects of local administration of these pyridazinone derivs. in a mouse model of acute inflammation. We found that 6-Benzyl-3-methyl-4-phenylpyrazolo[3,4-d]pyridazin-7(6H)-one (CC4), Et 6,7-dihydro-6-ethyl-3-methyl-7-oxo-4-phenyl-thieno[2,3-d]pyridazine-2-carboxylate (CC6) and Et 6,7-dihydro-6-ethyl-3-methyl-4-phenyl-1H-pyrrolo[2,3-d]pyridazine-2-carboxylate (CC12) reduced the paw edema induced by zymosan in mice as rolipram (the PDE4 inhibitor prototype with anti-inflammatory activity) and indomethacin did. It is well known that rolipram locally administered induces some adverse effects such as hyperalgesia. Thus, we studied this effect after local administration of CC4, CC6 and CC12 in the formalin test. We found that CC6 induced hyperalgesic effects, whereas CC4 and CC12 did not change the nociceptive threshold.

Furthermore, we found that rolipram and CC6 reduced locomotor activity, whereas CC4 and CC12 did not change locomotor performance of the mice. Since CC4 and CC12 neither affected the nociceptive threshold nor changed the locomotor performance of mice, they appear more suitable than CC6 for future studies on animals and could be developed as an anti-inflammatory drug for humans.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:331944 CAPLUS Full-text
 DOCUMENT NUMBER: 143:43848
 TITLE: New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors
 AUTHOR(S): Feixas, Joan; Paola Giovannoni, Maria; Vergelli, Claudia; Gavalda, Amadeu; Cesari, Nicoletta; Graziano, Alessia; Dal Piaz, Vittorio
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Firenze, Sesto Fiorentino, Firenze, 50019, Italy
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(9), 2381-2384
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:43848
 GI



AB A series of pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones, e.g., I, were synthesized and evaluated for their PDE5 inhibitory activity. Potent PDE5 inhibitors with high selectivity vs. PDE6 isoenzymes was identified.
 REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:565225 CAPLUS Full-text
 DOCUMENT NUMBER: 141:106481
 TITLE: Preparation of pyridazin-3(2H)-ones as Phosphodiesterase 4 (PDE4) inhibitors
 INVENTOR(S): Dal Piaz, Vittorio; Aguilar Izquierdo, Nuria; Buil Albero Maria, Antonia; Carrascal Riera, Marta; Gracia Ferrer, Jordi; Giovannoni, Maria Paola; Vergelli, Claudia
 PATENT ASSIGNEE(S): Almirall Prodesfarma Sa, Spain

SOURCE: PCT Int. Appl., 212 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058729	A1	20040715	WO 2003-EP14722	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2211344	A1	20040701	ES 2002-3003	20021226
ES 2211344	B1	20051001		
CA 2512099	A1	20040715	CA 2003-2512099	20031222
AU 2003290110	A1	20040722	AU 2003-290110	20031222
EP 1575926	A1	20050921	EP 2003-782471	20031222
EP 1575926	B1	20080305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016883	A	20051025	BR 2003-16883	20031222
CN 1753876	A	20060329	CN 2003-80109897	20031222
JP 2006515302	T	20060525	JP 2004-562819	20031222
ZA 2005004943	A	20060830	ZA 2005-4943	20031222
MX 2005PA06809	A	20050908	MX 2005-PA6809	20050621
IN 2005CN01395	A	20070907	IN 2005-CN1395	20050624
NO 2005003614	A	20050926	NO 2005-3614	20050725
US 2006173008	A1	20060803	US 2005-539821	20051214
PRIORITY APPLN. INFO.:			ES 2002-3003	A 20021226
			WO 2003-EP14722	W 20031222
OTHER SOURCE(S):			MARPAT 141:106481	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1, R2 = independently H, acyl, hydroxycarbonyl, alkoxy carbonyl, monoalkyl/dialkyl/carbamoyl, (un)substituted alk(en/yn)yl, hetero/aryl, (un)saturated heterocyclyl, etc.; R3 = (un)substituted monocyclic or polycyclic hetero/aryl; R5 = (un)substituted alkoxy carbonyl, monocyclic or polycyclic hetero/aryl; R4 = H, OH and derivs., NH2 and derivs., (un)substituted alk(en/yn)yl, etc.; and their N-oxides and pharmaceutically acceptable salts] were prepared as potent and selective inhibitors of Phosphodiesterase 4 (PDE4). Four pharmaceutical compns. are given. For example, II was prepared by hydrogenation of 5-acetyl-4-amino-2-ethyl-6-(pyridin-3-yl)pyridazolo-3(2H)-one over Pd/C in ethanol, and reaction of the amine with 3-fluorophenylboronic acid in the presence of Cu(OAc)2/TEA/mol. sieves/CH2Cl2. Preferred I exhibited an IC50 value < 30 nM for the inhibition of PDE4. I and their pharmaceutical compns. are useful for prevention and

treatment of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis and irritable bowel disease (no data).

L19 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:815783 CAPLUS Full-text

DOCUMENT NUMBER: 138:378543

TITLE: Synthesis and evaluation of some pyrazolo[3,4-d]pyridazinones and analogues as PDE 5 inhibitors potentially useful as peripheral vasodilator agents

AUTHOR(S): Dal Piaz, Vittorio; Castellana, Maria Carla; Vergelli, Claudia; Giovannoni, Maria Paola; Gavalda, Amadeu; Segarra, Victor; Beleta, Jorge; Ryder, Hamish; Palacios, Jose Maria

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Florence, 50121, Italy

SOURCE: Journal of Enzyme Inhibition and Medicinal Chemistry (2002), 17(4), 227-233

CODEN: JEIMAZ; ISSN: 1475-6366

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:378543

AB A series of pyrazolo[3,4-d]pyridazinones and analogs, potentially useful as peripheral vasodilators, were synthesized and evaluated as inhibitors of PDE5 extracted from human platelets. Several of them showed IC50 values in the range 0.14-1.4 μ M. A good activity and selectivity profile vs. PDE6 was found for compound (6-benzyl-3-methyl-1-isopropyl-4-phenylpyrazolo[3,4-d]pyridazin-7(6H)-one). Structure-activity relationship studies demonstrated the essential role played by the benzyl group at position-6 of the pyrazolopyridazine system. Other types of pyridazinones fused with five and six membered heterocycles (pyrrole, isoxazole, pyridine and dihydropyridine), as well as some open models were prepared and evaluated. Besides the pyrazole, the best fused systems proved to be isoxazole and pyridine.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:154884 CAPLUS Full-text

DOCUMENT NUMBER: 137:362487

TITLE: Isoxazolo[3,4-d]pyridazinones and analogues as Leishmania mexicana PDE inhibitors

AUTHOR(S): Dal Piaz, Vittorio; Rascon, A.; Dubra, M. E.; Giovannoni, M. P.; Vergelli, C.; Castellana, M. C.

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universite Firenze, Florence, 50121, Italy

SOURCE: Farmaco (2002), 57(2), 89-96

CODEN: FRMCE8; ISSN: 0014-827X

PUBLISHER: Editions Scientifiques et Medicales Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of isoxazolopyridazinones and analogs has been prepared and evaluated as Leishmania mexicana phosphodiesterase (PDE) inhibitors. Some of the synthesized compds. showed a moderate PDE inhibitory activity at 100 μ M and preliminary structure-activity relationships were discussed.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1998:793835 CAPLUS Full-text

DOCUMENT NUMBER: 130:162741
TITLE: Heterocyclic-fused 3(2H)-pyridazinones as potent and selective PDE IV inhibitors: further structure-activity relationships and molecular modeling studies
AUTHOR(S): Dal Piaz, Vittorio; Paola Giovannoni, Maria; Castellana, Carla; Palacios, Jose Maria; Beleta, Jorge; Domenech, Teresa; Segarra, Victor
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Florence, 50121, Italy
SOURCE: European Journal of Medicinal Chemistry (1998), 33(10), 789-797
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:162741
AB A novel group of heterocyclic-fused 3(2H)-pyridazinones were synthesized and evaluated as PDE III and PDE IV inhibitors and their affinity for 3H Rolipram high affinity binding site was determined. The obtained data demonstrated that some of the new compds. are endowed with potent and selective PDE IV inhibitory activity and greatly attenuated affinity for the Rolipram high affinity binding site that seems to be responsible for unwanted effects. Theor. calcns., performed on representative compds., demonstrated the presence of three hydrogen-bonding acceptor regions, of which one looks quite different with respect to literature compds. This finding could explain the different pharmacol. profile of the title compds. with respect to the analogs reported in the literature.
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:262337 CAPLUS Full-text
DOCUMENT NUMBER: 126:311728
TITLE: Novel Heterocyclic-Fused Pyridazinones as Potent and Selective Phosphodiesterase IV Inhibitors
AUTHOR(S): Dal Piaz, Vittorio; Paola Giovannoni, Maria; Castellana, Carla; Palacios, Jose Maria; Beleta, Jorge; Domenech, Teresa; Segarra, Victor
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Florence, 50121, Italy
SOURCE: Journal of Medicinal Chemistry (1997), 40(10), 1417-1421
CODEN: JMCMA5; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 126:311728
AB A series of 6-aryl-4,5-heterocyclic-fused pyridazinones were designed and synthesized as selective phosphodiesterase (PDE) IV inhibitors. Biol. evaluation of these compds. demonstrated a good selectivity profile toward the PDE III family and exhibited greatly attenuated affinity for the Rolipram high-affinity binding site that seems to be responsible for undesirable side effects. Structure-activity relationships (SARs) studies showed that the presence of an Et group at pyridazine N-2 is associated with the best potency and selectivity profile.
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:732957 CAPLUS Full-text
 DOCUMENT NUMBER: 126:84307
 TITLE: Synthesis and evaluation as platelet aggregation inhibitors of 6-phenyl-2,4-substituted-3(2H)-pyridazinones and their rigid analogs benzo[h]cinnolin-3,5-diones
 AUTHOR(S): Dal Piaz, Vittorio; Ciciani, Giovanna; Giovannoni, Maria Paola; Franconi, Flavia
 CORPORATE SOURCE: Dip. Scienze Farmaceutiche, Univ. Firenze, 50121, Italy
 SOURCE: Drug Design and Discovery (1996), 14(1), 53-75
 CODEN: DDDIEV; ISSN: 1055-9612
 PUBLISHER: Harwood
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A series of 5-acyl-6-phenyl-2,4-substituted-3(2H)-pyridazinones and analogous benzo[h]cinnolin-3,5-diones with reduced flexibility has been prepared and evaluated as human platelet aggregation inhibitors. The 4-methylsulfoxide I was the most potent compound of the series ($IC_{50} = 1.2 \mu M$). SAR studies have shown the primary importance of an electroneg. substituent at position 4 and an acetyl group at position 5 of the pyridazine system for potent platelet aggregation inhibitory activity. Biol. tests performed on a group of representative compds. showed that these products have no effects on prostaglandins, thromboxanes, and nitric oxide biosynthetic pathways. Some of synthesized compds. produced a moderate increase of cAMP level in platelets which does not depend on adenylate cyclase stimulation. Tests performed on human platelet phosphodiesterase III have shown that these compds. are not inhibitors of this enzyme.

L19 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:100835 CAPLUS Full-text
 DOCUMENT NUMBER: 126:144201
 TITLE: Synthesis and evaluation as PDE IV inhibitors of 4,5-hetero-condensed-6-phenyl-3(2H)-pyridazinones
 AUTHOR(S): Dal Piaz, Vittorio; Giovannoni, Maria Paola; Castellana, Carla; Palacios, Jose Maria; Beleta, Jorge; Domenech, Teresa; Segarra, Victor
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Florence, 50121, Italy
 SOURCE: Acta Pharmaceutica Hungarica (1996), 66(Suppl.), S33-S34
 CODEN: APHGAO; ISSN: 0001-6659
 PUBLISHER: Ifjuszagi Lap- es Konyvkiado Vallalat
 DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A lecture with 9 refs. including discussion of the preparation and pharmacol. of the title compds.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 18 OF 18 WPIX COPYRIGHT 2008 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2004-535444 [52] WPIX
 DOC. NO. CPI: C2005-224330; C2005-192018 [76] [66]
 TITLE: New derivatives of pyridazine-3 (2H)-one are for
 manufacture of a medication for treatment of illnesses
 which are alleviated by inhibition of phosphodiesterase
 4

DERWENT CLASS: B03

INVENTOR: AGUILAR I N; AGUILAR IZQUIERDO N; ALBERO M A B; BUIL
 A M A; BUIL ALBERO M A; CARRASCAL R M; CARRASCAL
 RIERA M; DAL PIAZ V; FERRER J G; GARCIA F J;
 GIOVANNONI M P; GRACIA FERRER J; IZQUIERDO N A;
 RIERA M C; VERGELLI C; GRACIA F J

PATENT ASSIGNEE: (LALM-C) ALMIRALL PRODESFARMA SA; (AGUI-I) AGUILAR I N;
 (BUIL-I) BUIL A M A; (CARR-I) CARRASCAL R M; (DPIA-I) DAL
 PIAZ V; (GIOV-I) GIOVANNONI M P; (GRAC-I) GRACIA F J;
 (VERG-I) VERGELLI C

COUNTRY COUNT: 107

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
ES 2211344	A1	20040701	(200452)*	ES	1[1]	
WO 2004058729	A1	20040715	(200452)	EN		
AU 2003290110	A1	20040722	(200476)	EN		
EP 1575926	A1	20050921	(200566)B	EN		
ES 2211344	B1	20051001	(200566)	ES		
BR 2003016883	A	20051025	(200571)	PT		
NO 2005003614	A	20050926	(200576)B	NO		
TW 2004018841	A	20041001	(200608)	ZH		
MX 2005006809	A1	20050901	(200617)	ES		
JP 2006515302	W	20060525	(200635)	JA	146	
KR 2005087868	A	20050831	(200648)	KO		
CN 1753876	A	20060329	(200649)	ZH		
US 20060173008	A1	20060803	(200651)	EN		
ZA 2005004943	A	20060830	(200662)	EN	212	
IN 2005CN01395	P4	20070907	(200805)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
ES 2211344	A1	ES 2002-3003	20021226
AU 2003290110	A1	AU 2003-290110	20031222
BR 2003016883	A	BR 2003-16883	20031222
CN 1753876	A	CN 2003-80109897	20031222
EP 1575926	A1	EP 2003-782471	20031222
WO 2004058729	A1	WO 2003-EP14722	20031222
BR 2003016883	A	WO 2003-EP14722	20031222
MX 2005006809	A1	WO 2003-EP14722	20031222
JP 2006515302	W	WO 2003-EP14722	20031222
KR 2005087868	A	WO 2003-EP14722	20031222
US 20060173008	A1	WO 2003-EP14722	20031222

EP 1575926 A1	WO 2003-EP14722 20031222
TW 2004018841 A	TW 2003-136605 20031223
JP 2006515302 W	JP 2004-562819 20031222
ZA 2005004943 A	ZA 2005-4943 20031222
MX 2005006809 A1	MX 2005-6809 20050621
KR 2005087868 A	KR 2005-712084 20050624
NO 2005003614 A	NO 2005-3614 20050725
US 20060173008 A1	US 2005-539821 20051214
IN 2005CN01395 P4	WO 2003-EP14722 20031222
IN 2005CN01395 P4	IN 2005-CN1395 20050624

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
AU 2003290110	A1	Based on	WO 2004058729	A
BR 2003016883	A	Based on	WO 2004058729	A
MX 2005006809	A1	Based on	WO 2004058729	A
JP 2006515302	W	Based on	WO 2004058729	A
EP 1575926	A1	Based on	WO 2004058729	A
KR 2005087868	A	Based on	WO 2004058729	A

PRIORITY APPLN. INFO: ES 2002-3003 20021226

AN 2004-535444 [52] WPIX

AB EP 1575926 A1 UPAB: 20060203

NOVELTY - The new derivatives of pyridazine - 3 (2H)-one are for the manufacture of a medication for treatment of illnesses which are alleviated by the inhibition of phosphodiesterase 4. In the formula, R1 and R2 each represent independently an atom of hydrogen or organic groups. R3 represents a monocyclic or polycyclic aryl or heteroaryl, which optionally is for substitution with one or more selected substitutes from atoms of halogen or organic groups.

DETAILED DESCRIPTION - R5 represents a -COOR7 group or a monocyclic or polycyclic aryl or heteroaryl group, which can optionally be substituted by one or more substitutes selected from atoms of hydrogen or organic groups.

USE - For manufacturing a medication for treatment of illnesses which are alleviated by inhibition of phosphodiesterase 4.

ADVANTAGE - Illnesses are alleviated by inhibition of phosphodiesterase 4.

DESCRIPTION OF DRAWINGS - The figure presents the formula (1) relating to the new derivatives of the pharmaceutical.

formula (1)

each represents independently an atom of hydrogen or an anic groups (R1,R2)

represents a monocyclic or polycyclic aryl or heteroaryl (R3)

represents a -COOR7 group of a monocyclic or polycyclic aryl or heteroaryl group (R5)

Member(0004)

ABEQ EP 1575926 A1 UPAB 20060203

NOVELTY - The new derivatives of pyridazine - 3 (2H)-one are for the manufacture of a medication for treatment of illnesses which are alleviated by the inhibition of phosphodiesterase 4. In the formula, R1 and R2 each represent independently an atom of hydrogen or organic groups. R3 represents a monocyclic or polycyclic aryl or heteroaryl, which optionally is for substitution with one or more selected substitutes from atoms of halogen or organic groups.

DETAILED DESCRIPTION - R5 represents a -COOR7 group or a monocyclic or polycyclic aryl or heteroaryl group, which can optionally be

substituted by one or more substitutes selected from atoms of hydrogen or organic groups.

USE - For manufacturing a medication for treatment of illnesses which are alleviated by inhibition of phosphodiesterase 4.

ADVANTAGE - Illnesses are alleviated by inhibition of phosphodiesterase 4.

DESCRIPTION OF DRAWINGS - The figure presents the formula (1) relating to the new derivatives of the pharmaceutical.

formula (1)

each represents independently an atom of hydrogen or an anic groups (R1,R2)

represents a monocyclic or polycyclic aryl or heteroaryl (R3)

represents a -COOR⁷ group of a monocyclic or polycyclic aryl or heteroaryl group (R5)

=> d his nofil

(FILE 'HOME' ENTERED AT 11:05:08 ON 14 MAR 2008)

FILE 'REGISTRY' ENTERED AT 11:05:19 ON 14 MAR 2008

L1 STR
L2 42 SEA SSS SAM L1
L3 927 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 11:09:52 ON 14 MAR 2008

L4 9 SEA ABB=ON PLU=ON L3
L5 6 SEA ABB=ON PLU=ON L4 AND (PY<2004 OR AY<2004 OR PRY<2004)
L6 3 SEA ABB=ON PLU=ON L4 NOT L5
D IBIB 1-3

FILE 'CAPLUS, DISSABS, CONFSCI, WPIX' ENTERED AT 11:11:59 ON 14 MAR 2008

E DAL PIAZ V/AU
E E3-5
E DALPIAZ V/AU
E PIAZ V/AU
L*** DEL 87 S E4-5 OR DAL PIAZ V?/AU
L7 88 SEA ABB=ON PLU=ON ("PIAZ V D"/AU OR "PIAZ V DAL"/AU OR "PIAZ VITTORIO D"/AU) OR DAL PIAZ V?/AU
E IZQUIERDO N/AU
L8 8 SEA ABB=ON PLU=ON ("IZQUIERDO N"/AU OR "IZQUIERDO N A"/AU OR "IZQUIERDO NURIA"/AU)
E IZQUIERDO A/AU
E IZQUIERDO/AU
E ALBERO M/AU
L9 9 SEA ABB=ON PLU=ON ("ALBERO M"/AU OR "ALBERO M A"/AU OR "ALBERO M A B"/AU)
E RUBIO Y/AU
L*** DEL 5 S RUBIO Y?/AU
E GARRIDO RU/AU
L10 7 SEA ABB=ON PLU=ON RUBIO Y?/AU OR GARRIDO RUBIO Y?/AU
L11 57 SEA ABB=ON PLU=ON GIOVANNONI M?/AU OR PAOLA GIOVANNONI M?/AU
L12 718 SEA ABB=ON PLU=ON FERRER J?/AU OR GRACIA FERRER J?/AU
L13 8 SEA ABB=ON PLU=ON AMADOR W?/AU OR LUMERAS AMADOR?/AU
L14 21 SEA ABB=ON PLU=ON VERGELLI C?/AU
L15 832 SEA ABB=ON PLU=ON (L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14) OR AGUILAR IZQUIERDO N?/AU OR BUIL ALBERO M?/AU OR ANTONIA BUIL ALBERO?/AU
L16 65 SEA ABB=ON PLU=ON L15 AND ?PYRIDAZIN?

L17 44 SEA ABB=ON PLU=ON L15 AND (PDE? OR PHOSPHODIESTER?)
L18 22 SEA ABB=ON PLU=ON L16 AND L17

FILE 'CAPLUS' ENTERED AT 11:28:38 ON 14 MAR 2008

 D QUE L5
 D L5 IBIB ABS HITSTR TOT
 D QUE L6

FILE 'CAPLUS, DISSABS, CONFSCI, WPIX' ENTERED AT 11:29:39 ON 14 MAR 2008

L19 18 DUP REM L6 L18 (7 DUPLICATES REMOVED)
 ANSWERS '1-17' FROM FILE CAPLUS
 ANSWER '18' FROM FILE WPIX
 D L19 IBIB ABS TOT